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Severe sepsis is defined as a systemic inflammation leading to organ failure and is characterized 
by the release of pro- and anti-inflammatory markers called cytokines.  Current clinical 
techniques used to treat sepsis such as early goal-directed therapy, specific-target drug therapies, 
and hemofiltration have had limited success and inconsistent outcomes.  A newly investigated 
therapy, hemoadsorption, has proven to be nonselective and therefore broad-spectrum (i.e. 
restores homeostasis to the system as a whole); more efficient and cost-effective than affinity-
based removal; and is auto-regulating in that solutes at higher concentrations are removed more 
rapidly than those at lower, safer concentrations.  The goal of this thesis was to characterize and 
compare adsorption profiles of several cytokines in our cytokine adsorption device (CAD) for 
use in the treatment of sepsis.  To do this, we first characterized capture of our three main 
cytokines of interest in the original lot of CytoSorb resin for buffer and serum. This polymer is a 
highly porous polymer manufactured by Cytosorbents, Inc. (Monmouth Junction, NJ) and 
consists of a polystyrene divinylbenzene (PSDVB) copolymer covered in a biocompatible 
polyvinylpyrrolidone coating.  We then detailed changes in adsorption profiles over a 
manufacturer’s lot change and re-established our baseline capture rates with the main cytokines 
of interest as well as a secondary group of cytokines in both buffer and serum. Further 
investigation into a lot of smaller diameter polymer followed and a re-design of our CAD 
ensued.  Finally, we tested the polymer in three distinct red blood cell suspensions in order to 
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 v 
methodically increase the degree of complexity of the capture suspension. With the information 
included in this thesis, further optimization and development to our CAD and the polymer will 
be done.  Additionally, the characterization of the resin is crucial for our in-house mathematical 
model as well as the development and calibration of a systems model of sepsis.  This model will 
be used to simulate the development and progression of sepsis in humans and the integration of a 
therapeutic CAD intervention protocol into the timecourse of sepsis to improve patient 
outcomes.   
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1.0  INTRODUCTION 
In noncardiac intensive care units, sepsis represents the largest cause of death [1].  Severe sepsis 
is defined as an infection that results in systemic inflammation, resulting in organ failure and 
death [2].  In the United States alone, more than 750,000 people each year are affected with a 
mortality rate greater than 30% [3, 4].  In addition, total annual costs associated with care for 
septic patients in the United States were greater than $16.7 billion in 2001 [4], and because 
sepsis affects the elderly at the highest rates, the incidence and cost of sepsis will continue to rise 
[5].  For survivors, detrimental effects of sepsis such as increased risk of death and increased 
medical costs associated with repeated hospitalizations remain for many years, resulting in a 
poor quality of life [4, 6]. Despite advances in medicine and research, understanding of the 
pathophysiology of sepsis and septic shock remains incomplete. Due to its high incidence, high 
mortality and morbidity, high cost, and complexity, sepsis is a major challenge faced in clinical 
medicine today. 
1.1 OVERVIEW OF SEPSIS  
As with most diseases and syndromes, sepsis is a progressive disorder and includes several 
stages, the definitions of which were laid out by the American College of Chest Physicians 
(ACCP) and the Society of Critical Care Medicine (SCCM) at a conference in 1991 in Chicago.  
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These stages, describing the inflammatory response to infection, include systemic inflammatory 
response syndrome (SIRS), sepsis, severe sepsis, and septic shock [2, 4]. 
 Systemic inflammatory response syndrome or SIRS is the first stage of sepsis that is 
diagnosed.  Patients with two or more of the following vitals are described as having SIRS: heart 
rate greater than 90 beats per minute, body temperature less than 36 oC (96.8 oF) or greater than 
38 oC (100.4 oF), respiratory rate greater than 20 breaths per minute or a PaCO2 less than 32 mm 
Hg on a blood gas analyzer, and a white blood cell count less than 4000 cells/mm3 or greater 
than 12000 cells/mm3 or the presence of greater than 10% immature neutrophils [4].  These 
criteria are nonspecific and general, reflecting the numerous and divergent individual diseases 
that can lead to a systemic inflammatory response that make studying and understanding the 
disease such a challenge.  As a result, the incidence of SIRS is extremely high, with estimates of 
30% of all in-hospital patients, greater than 50% of all ICU patients, and more than 80% of 
surgical patients in any given hospital meeting the criteria for SIRS [7].   
A landmark study by Rangel-Frausto et al. examined the incidence and progression of 
SIRS in three ICUs and three hospital wards over seven months at academic medical centers, 
substantiating the high incidence estimates.  Of 3708 patients admitted, more than 68% met 
criteria for SIRS; patients with SIRS had a 26% chance of developing sepsis, 18% chance of 
developing sever sepsis, and a 4% chance of developing septic shock.  Patients with two SIRS 
criteria at admission had a mortality of 6% compared to 3% without SIRS, while patients with 
three criteria had a mortality of 9%, and those meeting all four criteria had a mortality of 18% 
[8].   
Sepsis is defined as a patient who meets SIRS criteria in response to a known infection 
source, as diagramed in Figure 1, with typical vital signs including:  fever, tachypnea, 
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tachycardia and hypotension [1].   In most epidemiological studies, pulmonary, gastrointestinal, 
urinary tract, and bloodstream infections are the most common sources of infection in patients 
with sepsis or severe sepsis, accounting for approximately 80% of all sites.  In addition to 
infection site, incidence by which sepsis is acquired has also been examined.  Specifically, 
community acquired infections account for more than 55% of severe sepsis that requires 
hospitalization, while the remaining 44% are nosocomial and are caused by infections acquired 
in the hospital [4].   
 
 
Figure 1: Representation of overlap between SIRS, sepsis, and severe sepsis [4] 
 
The high incidence and numerous causes of SIRS and sepsis are reflected in the varying degrees 
of susceptibility of patients, with demographic variables and co-morbidities accounting for some 
of the variability.  Demographic traits that put a patient at a higher risk include being male, 
African American, elderly (over 65 years of age), and living in poverty.  Risk factors for 
increased susceptibility for the disease include co-morbidities such as diabetes, cancers, 
alcoholism, HIV infection, and immunosuppression agents.  Also, studies have identified a 
seasonal change in the incidence of sepsis, with winter months having higher rates [4, 9, 10]. 
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Severe sepsis is the progression of the systemic response to inflammation and infection to 
the point where the patient develops acute organ dysfunction.  Organs typically affected include 
lung, kidney, and cardiovascular systems with clinical indications outlined in Table 1, below.  
Septic shock is defined for those patients with severe sepsis and acute cardiovascular dysfunction 
[1, 7]. 
 
Table 1: Affected organs and clinical indications in severe sepsis [1] 
Central Nervous System Encephalopathy  
Delirium 
Cardiopulmonary Increased cardiac output 
Decreased systemic vascular resistance 
Hypotension 
Metabolic acidosis hyperlacatemia 
Acute lung injury, hypoxemia 
Acute respiratory distress syndrome (ARDS) 
Renal Decreased urinary output 
Acute tubular necrosis 
Gastrointestinal Ileus 
Elevated bilirubin 
Dermatology Ecthyma gangrenosum 
Symmetrical peripheral gangrene 
Acrocyanosis 
Toxic erythema 
Rash 
Other Metabolic 
        Hyperglycemia, hypoglycemia 
Hematologic 
         Leukocytosis, leucopenia 
         Thrombocytopenia 
          Disseminated intravascular coagulation 
 
 
In order to better manage sepsis and develop more effective treatment options, an understanding 
of the pathophysiology and cellular mechanisms is important.  Although understanding is 
incomplete, it is generally accepted that two mechanisms result in sepsis, severe sepsis, and 
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septic shock:  extrinsic: toxins, endotoxin, protein particles from gram-positive bacteria, viruses, 
fungi; and intrinsic (or endogenous); pro-inflammatory mediators released into the blood stream 
[11]. 
Endotxin, a lipopolysaccharide (LPS), can directly activate macrophages, endothelial 
cells, and complement.  This activation results in the release of proinflammatory mediators, or  
proinflammatory cytokines, such as: tumor necrosis factor (TNF), interleukin-1 (IL-1), 
interleukin-6 (IL-6), high mobility group box-1 protein (HMG-B1), macrophage migratory 
inhibitory factor (MIF), platelet activating factor (PAF), nitric oxide (NO), complements, and 
eicosonoids.  Similarly, gram-positive bacteria may cause septic shock that is impossible to 
differentiate from gram-negative bacteria.  The binding of LPS or proteins from gram-positive 
bacteria to the surface molecule CD14 on macrophages, monocytes, and neutrophils relays a 
signal through a transmembrane protein called the toll-like receptor (TLR).  Signals from the 
CD14/TLR complex activate nuclear factor κB (NK- κB) by phosphorylation cascades, causing 
NK- κB to move from the cytoplasm to the nucleus.  This translocation of NK- κB promotes the 
production of cytokines by target genes. Cytokines are defined as small proteins approximately 
25 kDa that are released by cells in response to a stimulus and induce a signaling pathway 
through receptors.  A chemokine is a subgroup of cytokines that have chemoattractant properties, 
causing cells to migrate towards the chemokine [12].  The systemic release of cytokines into the 
bloodstream is characteristic of sepsis and is strongly correlated to organ failure and death [13].  
This organ damage then leads to further cytokine release, which further damages organs, 
resulting in more cytokine production.  The production of cytokines, then, is redundant and 
difficult to manage.  
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Viruses, which can cause injury to host cells, do so by direct lysis of host cells, lysis of 
distant organ cells due to activated complement pathway, or are the result of circulating 
proinflammatory cytokines released in response to the presence of the virus.  Particles on viruses 
can also bind CD14 directly, activating the NK- κB pathway.  Finally, particles of fungi can 
activate macrophages, endothelial cells, and complements, with some fungal infections directly 
interacting with TLRs on cell membranes, activating the NK- κB pathway and therefore inducing 
the production of cytokines [11]. 
Intrinsic factors are released as a result of activation of the immune system by external 
stimuli such as severe infections, burns, trauma, and hemorrhage and include 
cytokines/chemokines (TNF, IL-1, IL-6, IL-8, HMG-B1, and MIF) and noncytokine mediators 
(NO, PAF, and complements) [11].  Important cytokine and chemokine mediators for this study 
will be outlined in section 1.2. 
Noncytokine mediator nitric oxide (NO) is a free radical with cytotoxic properties and 
can be formed by synthesis in cendothelial cells, in the brain, and by macrophages (which is 
triggered by TNF, IL-1, or PAF).  The action of NO results in decreased intracellular calcium, 
causing vascular and nonvascular smooth muscle relaxation.  In sepsis, this relaxation of smooth 
muscles results in hypotension.  Additionally, NO inhibits platelet adhesion and aggregation as 
well as polymorphonuclear (PMN) chemotaxis.  Another noncytokine mediator, platelet 
activating factor (PAF), is synthesized by endothelial cells, macrophages, and neutrophils.  In the 
presence of endotoxin, it is released and promotes aggravation and adhesion of platelets, 
thrombosis, and vascular injury as well as enhancing PMN chemotactic responses [11]. 
In addition to the release of cytokines, sepsis is complicated by other cellular 
mechanisms.  For example, when infection is introduced into the body, activation of complement 
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via the alternate pathway may take place.  Here, LPS is able to activate C3, signaling the start of 
the cascade.  Activated C3 and C5 are anaphylatoxins and potent vasodilators.  Excessive 
activation of complement can result in organ damage and has been hypothesized to contribute to 
hemodynamic collapse in septic shock [11]. 
1.2 INFLAMMATORY MEDIATORS OF INTEREST 
As described above, sepsis is characterized by a surplus of inflammatory mediators called 
cytokines in the bloodstream. This release of cytokines, both pro- and anti-inflammatory, is 
associated with organ failure and death [13].  Several published studies have examined which 
cytokines may be most important in effectively identifying the disease, identifying patients at 
higher risk of mortality, and guiding treatment options over the course of the disease [11, 14-16].  
The presence and concentration of specific cytokines and chemokines can then be considered 
biomarkers, or “characteristics objectively measured and evaluated as indicators of normal 
biological processes, pathogenic processes, or pharmacological responses to a therapeutic 
intervention,” to be measured and carefully monitored over the timecourse of the patient [16]. 
These biomarkers, in addition to being ideally rapidly available and easy to assay, would also be 
potential targets for therapy. 
In our laboratory, three important cytokine mediators of sepsis to be studied were chosen 
based on data from the largest sepsis study to date, the results of an observational study called 
GenIMS at the University Of Pittsburgh School Of Medicine, Department of Critical Care.  This 
study, which analyzed more than 1600 patients at 30 sites in the Eastern United States, found that 
plasma levels of interleukin 6 (IL-6), tumor necrosis factor (TNF), and interleukin 10 (IL-10) on 
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the day of presentation were higher in those patients that died in the hospital compared to those 
that were discharged alive [17].  A conclusion of the GenIMS study was that those three 
cytokines were important for predicting outcomes in sepsis and were, therefore, significant to 
modulate using hemoadsorption (discussed in section 1.4.1) [17].   For that reason, our 
laboratory focuses on the removal kinetics of IL-6, TNF, and IL-10, with each cytokine 
suspended by itself in solution to avoid possible effects of competition.  These three cytokines as 
well as additional secondary cytokines such as IL-1, IL-8, and HMG-B1 will be characterized 
thoroughly in the following chapters in several different suspensions and devices.   
IL-6 is a 21-26 kDa glycoprotein and is considered both a pro- and anti-inflammatory 
mediator, involved in the immune response, inflammation, and hematopoiesis [18].  It is 
produced by activated B cells, activated T lymphocyte, activated monocytes, and endothelial 
cells and has a relatively long half-life, making measurements in serum reliable and 
uncomplicated.   It is one of the initial cytokines released in inflammation, making it a potential 
early predictor in the time course of sepsis [11, 16]; however, it is a comparatively nonspecific 
marker of infection, elevated in many inflammatory states [16].  The release of IL-6 induces T-
cell and B-cell proliferation, as well as the production of acute-phase proteins.  These proteins, 
produced in the liver, are the result of inflammation or tissue injury, although their actual roles 
are not well understood [11]. 
TNF is a 51.9 kDa trimer classified as a pro-inflammatory cytokine and is secreted in 
large quantities by activated macrophages during sepsis and septic shock.  It is an important 
mediator of inflammation, causing fever, hypotension, shock-like syndrome, organ dysfunction, 
and activation of PMN and endothelial cells and has been indicated in the development certain 
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types of cancer [19].  The production of TNF results in production of complement components, 
NO, cell adhesion molecules, and IL-1, IL-6, IL-8, and IL-10 [18]. 
Finally, IL-10 is a 17-21 kDa dimeric protein classified as an anti-inflammatory cytokine 
that can down-regulated activated macrophages.  Produced by epithelial cells, monocytes, and 
lymphocytes during inflammatory states, its plasma levels have been shown to correlate to state 
of shock, TNF plasma concentrations, and organ injury [18]. 
1.3 CURRENT CLINICAL THERAPIES 
Clinical treatment for severe sepsis has been approached several ways, each to varying degrees 
of success and failure.  In general, patients have been treated using hemodynamic support and 
intensive care; early goal-directed therapy (EGDT); specific and broad-spectrum drug therapies; 
and hemofiltration. Typically, the use of one therapy over another is varied, with location of care 
and knowledge of the attending physician guiding therapy choice [20].  Unfortunately, each 
therapy currently used clinically has limitations associated with its use as indicated by the high 
mortality rate of sepsis despite these treatments being accessible to most.  The individual 
therapies and their limitations will be discussed further in the following section. 
1.3.1 Hemodynamic support and intensive care 
Before innovative techniques such as drug therapies and filtration, the standard of care for sepsis 
included hemodynamic support and intensive care.  For many ICUs, this is still the most 
common method of care practiced and includes monitoring vital signs, central venous pressure, 
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and urinary output to achieve specific hemodynamic endpoints [21].  According to a publication 
by a panel of the American College of Critical Care Medicine of the Society of Critical Care 
Medicine regarding practice parameters for hemodynamic support, there are three main 
components in treating sepsis and septic shock:  the first priority is to achieve and maintain a 
reasonable mean arterial pressure and cardiac output to maintain vitals; next, infection should be 
identified and eliminated; finally, a later goal includes disrupting the progression of the disease 
to septic shock.  During the time the patient is in the ICU, organ perfusion and function must be 
maintained and monitored [21]. 
From the guidelines of the ACCM, the following basic principles for hemodynamic 
support were established [21]: 
1. Resuscitate patients quickly and actively.  Perfusion of organs and tissues should 
be addressed early on for improved outcomes.  
2. Treatment of patients with severe sepsis of septic shock should take place in an 
ICU with continuous EKG and arterial oxygen monitoring. 
3. Arterial cannulation is recommended in order to provide more accurate 
monitoring of intra-arterial pressure and beat-to-beat analysis.  More accurate 
monitoring allows for physicians to adjust therapy quickly and effectively. 
4. End points of arterial pressure, heart rate, urine output, skin perfusion, mental 
status, and indexes of tissue perfusion (blood lactate concentration and venous 
oxygen saturation) should be met by adjusting therapy accordingly. 
5. Proper assessment of cardiac filling pressures may require catheterization.  
Echocardiography may also be used for ventricular volume and cardiac 
performance assessment. 
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In addition to the above guidelines, the ACCM also recommended three forms of therapy in 
order to achieve the end points in guideline 4 of proper arterial pressure, heart rate, urine output, 
skin perfusion, mental status, and indexes of tissue perfusion.  These therapies include fluid 
resuscitation, vasopressor therapy, and inotropic therapy. 
Recommendations of fluid therapy include the following: fluid infusion is the first step in 
treating a septic patient; isotonic crystalloids or iso-oncotic colloids may also be effective if 
titrated to endpoints; invasive hemodynamic monitoring may be required for those patients not 
responding to initial fluid infusions and should be used to monitor complications such as 
pulmonary edema; finally, hemoglobin concentrations should be monitored and maintained at 
recommended levels, especially in patients with low cardiac output, lactic acidosis, venous 
oxygenation desaturation, or cardiac or pulmonary disease.  Complications of fluid resuscitation 
include pulmonary and systemic edema resulting from increases in hydrostatic pressures, 
decreases in colloid osmotic pressures, and increases in microvascular permeability associated 
with septic shock [21]. 
ACCM recommendations for vasopressor therapy include the use of dopamine and 
norepinephrine to increase arterial blood pressure once the patient is adequately fluid 
resuscitated.  Phenylephrine is an alternative to increase blood pressure if tachyarrhythmias are 
present.  While low doses of dopamine to maintain renal function are not recommended. 
Replacement does steroids for those patients with hypotension may be beneficial, and low doses 
of vasopressors as a hormone replacement may also aid in raising blood pressure, although data 
has not been well established.  Complications of vasopressor therapy include significant 
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tachycardia, possible myocardial ischemia or infarction, decreased stroke volume and cardiac 
output, limp ischemia or necrosis, and impaired blood flow [21]. 
Finally, the first of several recommendations for inotropic therapy describes that 
dobutamine is a first choice for patients with low cardiac index and/or low mixed venous blood 
saturation after fluid resuscitation.  For patients with hypoperfusion, doutamine may help 
increase cardiac index and vasodpressors such as norepinephrine may be titrated separately from 
one another to maintain mean arterial pressure and cardiac output.  Complications of inotropic 
therapies include significant tachycardia or other cardiac arrhythmias, possible myocardial 
ischemia or infarction, necrosis of myocardial tissue, reduction in blood pressure, or possible 
impaired blood flow [21]. 
Hemodynamic support and intensive care has been and continues to be a prominent 
method for caring for patients with sepsis, severe sepsis, and septic shock.  Unfortunately, this 
method includes many complications and, according to several published studies, does not result 
in a consistent, significant improvement in the mortality and morbidity of sepsis [19, 22]. 
1.3.2 Early goal-directed therapy (EGDT) 
Early goal-directed therapy is a therapy designed to address inconstancies and deficiencies in 
hemodynamic support and intensive care.  The argument against hemodynamic support and 
intensive care is based upon the fact that vital signs, venous pressure, urinary output, and 
physical findings are inadequate to detect global tissue hypoxia.  To address these inadequacies, 
EGDT includes goal-oriented management of cardiac preload, afterload, and contractility to 
maintain equilibrium between systemic oxygen delivery and oxygen demand [19, 23]. 
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One study conducted by Rivers et al. investigated the potential benefit of EGDT in sepsis 
patients compared to controls (hemodynamic support and intensive care) [22].  In this study 263 
patients were randomly assigned to EGDT or control groups, with no significant differences in 
either group concerning baseline characteristics at admittance.  During the course of the study, 
those patients in the control group were given care at the attending doctors’ discretion following 
a protocol for hemodynamic support, similar to that found in section 1.3.1, and were admitted to 
inpatient beds as soon as possible.  Those patients in the experimental group received EGDT 
therapy as shown in Figure 2 for at least six hours in the emergency department before being 
transferred to inpatient beds.  The study found that those patients with EGDT had an in-hospital 
mortality of 30.5% compared to 46.5% for the control.  Additionally, patients in the EGDT 
group had significantly higher mean central venous oxygen saturation, lower lactate 
concentration, lower base deficit, and a higher pH, and less severe organ dysfunction than those 
in the control group. 
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Figure 2:  Protocol for EGDT [19, 22] 
 
Although EGDT in this one study did seem to significantly increase the rate of survival, debate 
still exists concerning the diagnostic and therapeutic interventions used and this method is not 
used universally.  Additionally, as with many studies on the mortality of sepsis, further and 
broader studies should be implemented in order to discover the true significance of the method 
[19, 24]. 
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1.3.3 Drug therapies 
In sepsis, drug therapies traditionally pursue one specific target in an attempt to down-regulate 
pro-inflammatory markers or limit the response of the immune system.  For example, a clinical 
trial by Abraham et al. focused on the use of a specific antagonist of TNF, murine TNF 
monoclonal antibody (TNF mAb), for the treatment of sepsis.  In this study 1879 patients were 
randomly assigned a single infusion of TNF mAb or a placebo consisting of human serum 
albumin with mortality at 28 days being the main outcome measurement.   The group determined 
that there was no association between the use of the therapy and increased reversal of symptoms 
and deemed the drug ineffective in the treatment of sepsis [25].  Similarly, Fisher et al. 
conducted a clinical trial to test the efficacy of interleukin 1 receptor antagonist for the treatment 
of sepsis, specifically targeting IL-1 in an attempt to down-regulate that cytokine. In this study 
99 patients were randomly assigned to be given one of three different doses of IL-1RA or 
placebo in addition to standard supportive care outlined in section 1.3.1 with mortality at 28 days 
the main outcome.  This group determined that a slight dose-dependent survival advantage 
existed for those that were treated; however, the small n-value in this study was a major 
limitation in the evaluation of the results.  For both of these trials, failure of the specific 
antagonist is a result of the inability of the drugs to attenuate the entire response of sepsis [26]. 
Other specific mediators have also been used as a source for drug therapies.  For 
example, drotrecogin alfa (activated protein C) and corticosteroids have all been used for the 
treatment of sepsis to little success.  Studies by Bernard et al. and Agnus et al. showed a 
significant reduction in mortality using drotrecogin alfa, a protein with antithrombotic, 
antiinflammatory, and profibrinolytic properties; however in the first study the risk of bleeding 
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was also significantly increased and the second study indicated that the positive effects of the 
drug were only observed until discharge, with little effect after [3, 27]. 
Finally, Annane et al. reported on the results of a study using low doses of corticosteroids 
in order to treat septic shock.  In this study, 300 patients were randomly assigned to receive 
hydrocortisone and fludrocortisones or placebo to determine if improvement to 28-day survival 
were made. This group concluded that there was a significant increase in survival [28]; however, 
a subsequent publication in rebuttal of those results indicate that the patient population in the 
Annane et al. study was unfairly skewed and biased the results [29]. 
The lack of definite success in improving patient outcomes in the above randomized 
clinical trials of sepsis led to the development of more broad-spectrum cytokine modulation such 
as hemofiltration and hemoadsorption, discussed in the following sections. 
1.3.4 Hemofiltration 
Hemofiltration is the removal of solutes from the plasma by convection generated by a 
concentration gradient across a semi-permeable membrane.  This therapy is advantageous over 
those therapies targeting specific antagonists since it can restore homeostasis by nonspecific 
removal of both pro- and anti-inflammatory mediators [30, 31].  Additionally, this type of 
treatment is concentration-regulated, meaning that mediators of higher concentrations are 
eliminated at a higher rate compared to those mediators at a lower plasma level [32].  The 
regulation inherent in hemofiltration is important since it does not completely deplete levels of 
all inflammatory mediators in a septic patient, which may reduce the ability of the patient to fight 
infection.  Several studies utilizing hemofiltration have been able to demonstrate an early 
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decrease in cytokine concentration followed by a plateauing of removal with time [33-35].  With 
limited available surface area, it is clear that filters become saturated over time. 
Several studies have been able to demonstrate the hemofiltration using porous fibers is 
able to remove many different mediators of inflammation and thereby influence the plasma 
concentration of those mediators [33-35].  In one such study, circulating TNF concentrations in a 
small population of septic patients decreased during continuous veno-venous hemofiltration 
using an AN69 hemofilter (Hospal Multiflow 60, Cobe Renal Intensive Care, Lakewood, CO).  
The mechanism by which the TNF was removed by the filter was not through diffusive transport 
but by convective means.  Upon analysis of the ultrafiltrate, however,  low cytokine 
concentrations were found.  This indicated that adsorption of the cytokines to the filter 
membrane was the main mechanism by which TNF was removed [35].  Another study 
monitoring plasma levels of circulating IL-6 in septic rats during hemofiltration with a fiber 
module also came to the conclusion that the cytokines were being removed by nonspecific 
adsorption onto the  fibers in the filter [34].  Finally, a clinical study in Belgium using 
hemofiltration with an AN69 hemofilter (Multiflow 100, Hospal, France) determined that 
concentrations of IL-6, TNF, and IL-1β were significantly reduced and that the main mechanism 
of removal was through nonspecific adsorption to the membrane [33]. 
These studies using hemofiltration were able to demonstrate that the removal of cytokines 
by adsorption was an important mechanism involved in modulating the inflammatory response of 
a patient.  These filters are not designed for adsorption, however, and are severely limited by the 
lack of surface area of the fibers.  Accordingly, devices utilizing porous beads as an absorbent, 
with far greater available surface area, are more likely to succeed.   
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1.4 BEAD-BASED CYTOKINE ADSORPTION DEVICE 
1.4.1 Hemoadsorption  
Hemoadsorption involves perfusion of whole blood or plasma directly through a device with a 
sorbent material such as porous beads.  Blood purification by hemoadsorption is broad-spectrum 
due to the nonselective and concentration-dependant removal of both pro- and anti-inflammatory 
mediators (i.e. restores homeostasis to the system as a whole) [6]; is more efficient and cost-
effective than affinity-based removal; and is auto-regulating in that solutes at higher 
concentrations are removed more rapidly than those at lower, safer concentrations [32]. 
One type of hemoadsorption currently used clinically is the Lixelle polymer developed by 
a group in Japan.  This polymer has been shown to adsorb not only endotoxin, but also IL-1β, 
IL1-RA, IL-6, IL-8, and TNF with moderate efficiency both in rats and humans. The binding of 
both the endotoxin and the inflammatory mediators has been shown to significantly improve 
patient outcomes [15, 36-38].  From the same group, the development of a new column for the 
treatment of sepsis is also underway.  This device, known as CTR, works along the same 
principal as the Lixelle column but contains larger, porous cellulose beads that are able to 
remove hydrophobic substances circulating in the blood.  This polymer has a higher efficiency in 
adsorption of middle- to high-molecular weight molecules such as IL-6 and TNF due to carefully 
manufactured pore sizes that minimize adsorption of albumin and other high molecular weight 
proteins and preferentially targets smaller cytokines [36, 37]. 
Another adsorptive resin currently being developed is the CytoSorb™ polymer, used by 
our group for the development of a hemoadsorption device for the treatment of sepsis.  This 
polymer and its use in this work will be discussed thoroughly in the following section. 
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1.4.2 CytoSorbTM polymer 
The resin used in our device, CytoSorbTM, is a highly porous polymer manufactured by 
Cytosorbents, Inc. (Monmouth Junction, NJ) [39].  The bead consists of a polystyrene 
divinylbenzene (PSDVB) copolymer covered in a biocompatible polyvinylpyrrolidone coating 
and is approximately 300-600 µm in diameter with a density of 1.02 g/cm3 and a porosity 67.7%.    
Pore sizes in the beads range from 8-50 Å, allowing only smaller proteins to access the inside of 
the bead and excluding larger molecules such as albumin and fibrinogen.  Figure 3 shows both a 
close-up of the polymer (left) and an image of the inner pore structure of the bead (right). 
 
   
Figure 3: Images of CytoSorbTM  polymer (left) and inner pore structure (right) 
 
The use of a device that incorporates a biocompatible bead for nonspecific removal of cytokines 
is beneficial for several reasons.  Specifically, whole blood may be perfused directly through the 
packed column, eliminating the need for plasma separation.  Additionally, the surface area of 
CytoSorbTM polymer far exceeds that of fibers, with 850 m2/g compared to 0.5-2 m2/g.  Finally, 
nonspecific and concentration dependant removal of inflammatory mediates is a broad-spectrum 
approach that increases efficiency and decreases costs that would be associated with a system for 
specific removal [32].  Kellum et al. showed that columns packed with CytoSorbTM polymer 
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were able to remove over 50% of circulating IL-6, TNF, and Il-10 concentrations in one hour in 
a study of septic rats.  This removal was positively associated with increased survival times for 
animals of 21% compared to animals receiving sham treatment [40].   Another study using septic 
rats indicated a positive correlation between reduction in IL-6 and IL-10 with the CytoSorb™ 
polymer and mean survival times in septic rats [41].  Finally, a more recent study by Kellum et 
al. investigated the use of CytoSorb™ to remove cytokines from the blood of brain-dead 
humans.  In this study, results indicated that the polymer was able to remove significant levels of 
IL-6 and TNF, but not IL-10 [42].   
These studies indicate the significant removal of cytokines from the bloodstream as well 
as the positive effect hemoadsorption with the CytoSorb™ polymer has on survival outcomes for 
sepsis.  In order to develop and optimize this polymer and device, a greater understanding of the 
adsorptive profiles of cytokines in suspension is needed.  To do this, several different 
suspensions of increasing complexity from plain buffer to whole blood are needed to evaluate 
baseline polymer adsorption characteristics.  Additionally, alterations in bead lots and polymer 
characteristics need to be fully understood and developed.  Therefore, the goals of this thesis 
were to: 
• Characterize adsorption profiles of cytokines in buffer and serum in baseline 
polymer 
• Characterize and compare adsorption profiles across a change in bead lot and 
provide additional adsorption profiles for secondary cytokines of interest 
• Characterize and compare adsorption profiles of several cytokines in the CAD 
and newly engineered reCAD and modify an existing mathematical model to 
produce more a accurate model fitting 
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• Characterize adsorption profiles of several cytokines spiked into red blood cells 
resuspended in plasma and serum as well as cytokines spiked into whole blood 
 
In this thesis, Chapter 2.0 discusses the design and fabrication of our CAD as well as results of 
cytokine capture in buffer and serum for our original bead lot.  Chapter 3.0 includes 
characterization and comparisons of changes in adsorption profiles over a manufacturer bead lot 
change.  Chapter 4.0 then investigates a change in the sorbent polymer, with a focus on change in 
diameter with smaller diameter beads characterized and examined.  Also in this chapter is the 
development and characterization of a newly engineered device, the reCAD, for use with small 
diameter polymer.  Chapter 5.0 discusses cytokine capture in red blood cell suspensions and 
healthy whole blood in detail.  Finally, Chapter 6.0 outlines the summary and conclusions of this 
work. 
 This characterization data is crucial not only for the validation and development of our 
own in-house mathematical model that will be discussed later, but also for the development and 
calibration of a systems model of sepsis developed by our colleagues [43].  This systems model 
will ultimately simulate the development and progression of sepsis in humans and the integration 
of a therapeutic CAD intervention protocol into the timecourse of sepsis to improve patient 
outcomes. 
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2.0  BASELINE BEAD CHARACTERIZATION 
As discussed in Chapter 1.0 nonspecific removal of cytokines from whole blood using a 
hemoadsorption device is broad-spectrum, more efficient and cost-effective, and auto-regulating 
compared to other more traditional therapies.  The development of a clinically used device, 
however, that utilizes biocompatible beads for direct blood perfusion has been absent from the 
literature.  Our group has been investigating a novel porous, biocompatible sorbent polymer for 
use in such applications and has developed a device called the Cytokine Adsorption Device, or 
CAD, for use in the treatment of sepsis.  In order to fully characterize such a polymer and device, 
recombinant human cytokines were spiked into suspensions of increasing complexity:  buffer, 
serum, and red blood cell suspensions of buffer, serum, or whole blood.  The more simplified 
suspensions allow us to understand the basic characteristics of cytokine removal with the 
polymer independent of the complexities inherent to whole blood perfusion, specifically 
biologically active molecules and soluble cytokine receptors in present in whole blood.  This 
chapter focuses on the first set of characterization capture experiments for the original lot of 
CytoSorbTM polymer, #101003, in both buffer and serum. 
A mathematical model was previously developed in-house in order to guide development 
of the device and characteristics of the polymer used.  Our mathematical model was derived in 
order to quantify and compare removal of cytokines from suspensions using different bead sizes, 
flow rates, reservoir volumes, suspensions, etc., and was developed by graduate student Morgan 
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Fedorchak and Dr. William Federspiel. This model accounts for both macroscale transport in the 
device as well as diffusion and adsorption within the beads.  The analysis published by DiLeo et 
al. yielded the following simple analytic expression for the removal rate of individual cytokines: 
 
    (1) 
 
where Q is the volumetric flow rate, Vr is the suspension reservoir volume, mb is the mass of 
beads in the column, R is the radius of bead in the column, and ρ is the density of the polymer 
[44].  The unknown parameter Γi, which is specific to the cytokine i and the particular polymer, 
is defined as  
 
      (2) 
 
where Di is the effective diffusion coefficient of cytokine i in the beads, qimax is the maximum 
capacity of cytokine i per unit mass of bead, and Ki is the affinity constant from the Langmuir 
equilibrium adsorption isotherm [44]. 
 To fit capture data to the model, concentrations of cytokines were normalized to initial 
concentration.  Capture data was then fit to the model by integrating the above equation using a 
program written for MATLAB® R2009a (The MathWorks, Inc., Natick, MA), found in 
Appendix A1, so that reduction in reservoir volume due to sampling could be 
accounted for.  Integration in MATLAB® was subject to the constraint that at t=0, the 
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normalized concentration is 1.  The unknown parameter Γi was determined by another program 
for nonlinear regression written in MATLAB®, also found in Appendix A.1. 
 Using this model and its lumped dimensionless output parameter, Γi, data sets between 
the different suspensions were compared and contrasted statistically for each of several cytokines 
in buffer and serum.  Results for capture in buffer and serum in this chapter are presented for the 
three main cytokines of interest: IL-6, TNF, and IL-10.  These baseline experiments were then 
used to make comparisons for other data sets presented later in this thesis. 
2.1 CAD DESIGN AND FABRICATION 
2.1.1 Design 
The Cytokine Adsorption Device (CAD) is a commercially available 1 mL RezorianTM cartridge 
(Supleco, Bellefonte, PA) with in-house modifications (see section 2.1.2) that is packed with our 
biocompatible polymer, Figure 4 (top).  The bead bed within the cartridge is approximately 1 cm 
in diameter and 3 centimeters in length, which is approximately 300 times smaller than a 
clinically used device, Figure 4 (bottom) [45].  This scaling factor was also used to scale our 
recirculation experiment set-up, specifically reservoir volume and flow rate.  From flow rates of 
150 to 300 mL/min for hemoadsorption used clinically [45] and total blood volume in a human 
being 4 to 6 L, plasma flow rate and reservoir (plasma) volume are scaled to 0.8-1.0 mL/min and 
8 mL, respectively (unless otherwise noted). 
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Figure 4: CAD (top) and full-sized cartridge (bottom), not to scale 
2.1.2 Fabrication 
Fabrication of the device requires modification of a commercially available cartridge to ensure a 
properly packed and secured bead bed.  To do this, a 3/16” diameter hole is punched through the 
center of a filter included in the 1 mL Rezorian tube kit (Supleco, Bellefonte, PA) using a 
stainless steel hand punch. With a small amount of clear RTV silicone adhesive sealant 
(Permatex, Solon, OH), a 5/16” in diameter 250 µm polyurethane mesh (Small Parts, Inc., 
Miramar, FL) disc is then glued to one side of the filter.  Using a small amount of clear RTV 
silicone adhesive sealant (Permatex, Solon, OH), a 1/4” in diameter 250 µm polyurethane mesh 
(Small Parts, Inc., Miramar, FL) disc is then glued to the inner side of the blue end cap.  Once 
the adhesive was completely dried, the CAD was assembled as shown in Figure 5, below, with 
caps screwed onto the ends of the device. 
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Figure 5: Schematic of CAD 
 
To ensure repeatability, devices were weighed before and after packing.  The mass was then 
compared to a set average mass established in-house, plus or minus one standard deviation, of 
1.49 g ± 0.075 g (1.416 g – 1.565 g).  This is to ensure that all of the cartridges are packed to the 
same specifications based on mass. 
2.1.3 Determination of polymer radius 
Using particle size distribution histograms provided by the manufacturer for each bead lot, we 
determined a weighted average radius of the beads supplied.  This weighted average was used in 
order to provide a better fit for our model since bead radius distributions are not normally 
distributed and provide a poorer fit.  An example of a mock histrogram used is shown in Figure 
6.  To determine the average bead radius, we first averaged the radius size ranges for each of the 
histogram bins provided and transformed the data with the equation: 
 
     (3) 
 
This value was then weighted by multiplying it with the percent volume given in the histogram.  
The average of the weighted values was then computed and transformed back using the inverse 
Filter Blue end cap 
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of the natural log.  This value, our in-house weighted average radius, was then used in our 
mathematical modeling to compare lots of beads. 
 
 
Figure 6:  An example of a mock histogram used for determining the weighted bead radius 
2.2 CAPTURE EXPERIMENTS 
2.2.1 Materials and methods 
In general, recirculation (capture) experiments in buffer and serum were done as follows.   A 
fabricated CAD was filled with CytoSorbTM polymer lot #101003 from Cytosorbents, Inc. 
(Monmouth Junction, NJ).  The mass of the device before and after filling was measured and 
recorded in order to ensure repeatability between trials, as described in section 2.1.2.  To connect 
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the CAD to tubing, a female 3/32” leur lock with a 5” piece of 3/32” ID (5/32” OD) Tygon 
tubing and a male 3/32” leur lock with a 5” piece of 3/32” ID (5/32” OD) Tygon tubing were 
connected to the appropriate ends of the CAD.  This was then connected to a 3/32” fitting for 
ready connection to a low-flow peristaltic pump (Fisher Scientific, Waltham, MA) and the other 
end of the fitting was connected to a 10” piece of 3/32” ID (5/32” OD) Tygon tubing, Figure 7. 
 
 
Figure 7: Schematic of capture experiment set-up [46] 
 
Once the tubing was attached to the pump head, the inlet end was placed in a beaker containing 
approximately 20 mL of PBS (pH 7.4) and the tubing and CAD were primed for at least 20 
minutes.  During this time, the pump was calibrated to the appropriate flow rate of 0.8-1.0 
 29 
mL/min, unless otherwise stated.  Additionally, the reservoir, containing 8 mL thawed horse 
serum or 8 mL PBS with 5% BSA was spiked with the appropriate recombinant human cytokine. 
Spiked concentrations of recombinant cytokines mimicked physiological concentrations for a 
septic patient, approximately 1000-5000 pg/mL.   
Once the tubing and CAD were fully primed, the inlet end of the tubing was removed 
from the reservoir to create approximately a 3 inch bubble of air in the tubing so that PBS would 
not enter the reservoir.  The tubing inlet was then placed in the reservoir containing the 
suspension of interest. The experiment began when the first drop of buffer/serum entered the 
reservoir from the outlet end of the tubing.  Sampling was done by pipetting 200 µL volumes 
from the reservoir and transferring to a labeled eppendorf tube for time points: 0 (baseline, 
before recirculation begins), 15, 30, 60, 90, 120, 180, and 240 minutes for all capture 
experiments.  Samples were then frozen at -80oC until they could be assayed. All samples were 
assayed using a solid phase sandwich Enzyme Linked Immunosorbent Assay (ELISA) purchased 
commercially, according to the instructions from the manufacturer (Invitrogen, Camarillo, CA or 
other, as noted). 
 
2.2.2 Statistical analysis 
To compare data sets for different cytokines or different suspensions, the average Γi value and 
standard deviation was calculated for each set of experiments, with n=3 unless otherwise stated.  Γi values were then compared using an independent t-test with p < 0.05 considered significant.  A 
one-way analysis of variance (ANOVA) was used to determine the significance of the mean Γi 
values between all three cytokines in each suspension.  When a significant F value was obtained, 
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further analysis with posthoc testing consisting of a Bonferroni correction was completed to 
determine significance.  
2.3 RESULTS AND DISCUSSION 
2.3.1 Capture of test cytokines in buffer 
As the simplest form of suspension, recombinant cytokines were spiked into 8 mL of PBS with 
5% BSA.  Figure 8 shows the results of IL-6 capture in buffer.  Error bars in this and all of the 
following figures for capture experiments indicate the standard deviation of three trials (n=3), 
unless otherwise specified. The average Γi value obtained over those three trials was 1.00E-4 ± 
1.8E-5 cm2⋅mL⋅min-1⋅g-1.  Total cytokine reduction was more than 90% at the end of the four 
hour capture experiment, with more than 50% of the initial cytokine concentration depleted in 
the first 30 minutes of capture. 
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Figure 8: IL-6 capture data and model fits for buffer 
 
Figure 9 shows the results of TNF capture in buffer. The average Γi value obtained over those 
three trials was 7.16E-5 ± 4.4E-6 cm2⋅mL⋅min-1⋅g-1. Total cytokine removal was more than 90% 
by the end of the four hour capture experiment, with more than 50% of the initial cytokine 
concentration depleted in the first 60 minutes of capture.   
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Figure 9: TNF capture data and model fits for buffer (error bars smaller than symbols)
 
For capture of IL-10 in buffer, results are shown in Figure 10, below.  The average Γi value 
obtained over those three trials was 5.65E-5 ± 6.8E-6 cm2⋅mL⋅min-1⋅g-1. Total cytokine removal 
was 90% at the end of the four hour capture experiment, with more than 50% of the initial 
cytokine concentration depleted in the first 60 minutes of capture.   
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Figure 10: IL-10 capture data and model fits for buffer 
 
A one-way ANOVA analysis of the three cytokines in buffer revealed that the mean Γi values of 
each cytokines were not statistically different (p=0.172); total cytokine removal for all three 
capture experiments remained at or slightly above 90% and overall trends of capture were the 
same for all three cytokines in buffer. 
2.3.2 Capture of test cytokines in serum 
In this part of the study recombinent human cytokines were spiked into 8 mL aliquots of horse 
serum in order to add another degree of complexity to the suspension medium.  This medium, 
unlike in plain buffer, includes receptors, growth factors, and other biologically active groups 
that may or may not have an effect on cpature and must be investigated.  Horse serum, an 
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alternative for human sera, is less expensive to obtain and does not present the additional 
compelexity of specific soluble receptors for human cytokines. Data obtained from this set of 
experiments was statisically compared to data from capture in buffer to determine if the two 
suspensions produce the same results.   
Figure 11 shows the results of IL-6 capture in horse serum. The average Γi value obtained 
over those three trials was 1.05E-4 ± 2.4E-5 cm2⋅mL⋅min-1⋅g-1 and was not significantly different 
compared to the Γ i values for IL-6 capture in buffer (1.00E-4 cm2⋅mL⋅min-1⋅g-1, p=0.78).  Total 
cytokine removal was 90% by the end of the four hour experiment, with more than 50% of the 
initial concentration depleted in the first 30 minutes.  These capture kinetics were identical to 
those found in IL-6 capture in buffer, also given in Figure 11.   As shown, the data are so closely 
related that it is difficult to differentiate between the two data sets. 
 
 
Figure 11: IL-6 capture data and model fits for serum and buffer 
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Results of TNF capture in serum are shown in Figure 12. The average Γ i value obtained over 
those three trials was 1.04E-5 ± 4.4E-6 cm2⋅mL⋅min-1⋅g-1 and was significantly different from 
TNF capture in buffer (7.16E-5 cm2⋅mL⋅min-1⋅g-1, p<0.01). Total cytokine removal was almost 
65% by the end of the four hour experiment, with less than 40% of the initial concentration 
depleted in the first 60 minutes. 
Our hypothesis for the decreased removal rate and total cytokine removal was due to the 
fact that the TNF molecule is biologically active in a trimeric form, which may be too large to 
diffuse efficiently into the pores when suspended in horse serum [47].  TNF, however, has been 
shown to dissociate into monomeric form in suspensions other than human serum, which may 
explain the significantly faster removal in simple buffer [48].  Additionally, the presence of TNF 
receptors, even if they are horse receptors, may have some impact on the removal rate of TNF in 
a serum suspension [49].  Investigation of this hypothesis is currently being done by other 
graduate students in our laboratory and is not within the scope of this thesis. 
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Figure 12: TNF capture data and model fits for serum and buffer 
 
Finally, Figure 13 shows the results of IL-10 capture in serum.  The average Γ i value obtained 
over those three trials was 4.12E-5 ± 2.3E-6 cm2⋅mL⋅min-1⋅g-1.  This value was not statistically 
different from the Γi values of IL-10 capture in buffer (5.65E-4 cm2⋅mL⋅min-1⋅g-1, p=0.17).  Total 
cytokine removal was approximately 90%, similar to that found in buffer capture.  
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Figure 13: IL-10 capture data and model fits for serum and buffer 
 
A one-way ANOVA analysis of the three cytokines in serum revealed that the mean Γi values of 
each cytokines were statistically different (p<0.01); total cytokine capture for all three capture 
experiments varied significantly, with TNF having the lowest overall removal and IL-6 and IL-
10 having similar total removal. Each of the three cytokines in buffer and serum, with their 
respective p values, are shown in Table 2, below. 
 
Table 2: Gamma (Γi) values for IL-6, TNF, and IL-10 in buffer and serum 
 Buffer Serum p value 
IL-6 1.00E-4 1.05E-4 p=0.78 
TNF 7.16E-5 1.04E-5 p<0.01 
IL-10 5.65E-4 4.12E-4 p=0.17 
 
 
 38 
These results, as the first and simplest sets of baseline experiments for capture of cytokines in 
our laboratory, show that hemoadsorption in a simple buffer suspension and a simple serum 
suspension with CytoSorb polymer is able to remove significant amounts of IL-6, TNF, and IL-
10.  The results from capture in serum are consistent with general trends for in vivo studies done 
in rats by Kellum et al. [34, 41].  In these studies, significant levels of cytokines IL-6 and IL-10 
were removed compared to sham circuit, which was absent a hemoadsorption column.  Levels of 
TNF were not significantly altered.  Due to the larger size of TNF and the possible interaction 
between recombinant human TNF and soluble TNF receptors, a reduced capture rate would be 
expected both in vitro and in vivo. 
 Further capture experiments in more complex suspensions are needed, however, for the 
development and validation our of in-house model as well as the systems model of sepsis 
currently being developed by our colleagues [43].  These systems models include complexities 
such as cytokine release and interactions of the cellular components of blood and are calibrated 
using capture data produced from our laboratory.  Capture in more complex systems will be 
detailed later in Chapter 5.0  with experimentation in red blood cell suspensions.  The work 
presented next, however, will detail the change in adsorption profiles during a change in the 
baseline polymer from one lot to the next followed by capture in polymer with a smaller 
diameter. 
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3.0  CHANGE IN CAPTURE DATA OVER MANUFACTURER LOT CHANGE 
At one point in the characterization process of the CytoSorbTM polymer, depletion of our sample 
of polymer lot #101003 occurred.  Cytosorbents, Inc., (Monmouth Junction, NJ) was able to 
manufacture and send two new cartridges of polymer, lot #070907/071007, which were to have 
the same characteristics of the previous lot, #101003 based on specifications used by the 
manufacturer during production.  The average radius, however, a weighted average determined 
by the histogram provided by Cytosorbents, Inc. and done in-house as explained in section 2.1.3, 
revealed a smaller average radius.  Characterization in serum and buffer was necessary, then, to 
ensure that the removal rate of cytokines with the new bead lots were statistically the same as the 
older lot of beads. 
We first examined capture for IL-6, TNF, and IL-10 in buffer then expanded our work to 
include capture of a secondary group of cytokines:  IL-1α, IL-1 receptor antagonist (IL-1RA), 
high mobility group box 1 (HMG-B1), and IL-8.  Details of these cytokines are included in 
section 3.2.2 along with capture profiles for buffer.  We then repeated our work in horse serum, 
comparing capture rates between buffer and serum in the new lot as well as comparing capture 
rates between the new and old lots of beads to determine if differences in the polymer lots 
existed.   
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3.1 CAPTURE EXPERIMENTS 
3.1.1 Materials and methods 
In general, materials and methods for capture experiments in buffer and serum in the new lot of 
beads was done exactly as described in section 2.2.1.   Fabricated CADs, however, were filled 
with CytoSorbTM polymer lot #070907/071007 from Cytosorbents, Inc. (Monmouth Junction, 
NJ).  
3.1.2 Statistical analysis 
To compare data sets for the two bead lots for each cytokines, the average Γi value and standard 
deviation was calculated for each set of experiments, with n=3 unless otherwise stated.  Γi values 
were then compared using an independent t-test with p < 0.05 considered significant and 
indicating a difference in the mean Γi values. 
3.2 RESULTS AND DISCUSSION 
3.2.1 Capture of test cytokines in buffer 
Again, as the simplest form of suspension, recombinant cytokines were spiked into 8 mL of PBS 
with 5% BSA. Figure 14 shows the results of IL-6 capture for the new bead lot (#070907) in 
buffer compared to the old bead lot (#101003). The average Γi value obtained over three trials 
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was 1.76E-4 ± 1.3E-5 cm2⋅mL⋅min-1⋅g-1 which was statistically different from the Γi value of IL-6 
capture in buffer in the original polymer (1.0E-4 cm2⋅mL⋅min-1⋅g-1, p<0.01).  Total cytokine 
removal was approximately 95%, an increase of almost 5% compared to the previous lot of 
beads. 
 
 
Figure 14: IL-6 capture data and model fits for both bead lots in buffer 
 
The next cytokine tested in the new lot of beads was TNF with results shown in Figure 15, 
below.  The average Γ i value obtained over three trials was 3.72E-5 ± 5.0E-6 cm2⋅mL⋅min-1⋅g-1 
which was statistically different from the Γ i value of TNF capture in the previous lot (7.15E-5 
cm2⋅mL⋅min-1⋅g-1, p<0.01).  Total cytokine removal was approximately 89%, a decrease of 5% 
compared to the previous lot of beads.  This decrease in capture rate and overall removal was 
surprising in light of IL-6 capture in the new bead lot, which showed faster removal. 
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Figure 15: TNF capture data and model fits for both bead lots in buffer 
 
IL-10 capture data in both lots of beads is found in Figure 16.  Here, the average Γ i value 
obtained over three trials was 1.95E-5 ± 1.02E-6 cm2⋅mL⋅min-1⋅g-1 which was statistically 
different from the Γ i value of IL-10 capture in the previous lot (7.15E-5 cm2⋅mL⋅min-1⋅g-1, 
p<0.05).  Total cytokine reduction was approximately 88%, a decrease of 5% compared to the 
previous lot of beads with over 94% removal. This decrease in capture rate and overall removal 
was the same trend as TNF in the new lot of beads, but different from IL-6 capture, which 
showed faster removal and greater overall removal. 
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Figure 16: IL-10 capture data and model fits for both bead lots in buffer 
 
In order to more easily compare the results of Chapter 2.0 and section 3.1, gamma values for capture 
in buffer for lots #101003 and #070907/071007 are found in Table 3, below.  For capture in 
buffer, it is clear that the two bead lots are not statistically the same with p-values for each set of 
experiments less than 0.05.  We hypothesized that differences in capture rates were attributed to 
possible differences in polymer lot characteristics, however, differences in capture were not 
consistent for all three cytokines with IL-6 removal increasing and TNF and IL-10 removal 
decreasing.  Slight differences in pore size resulting in smaller average pore diameters would 
reduce the apparent surface area accessed by the cytokines and thereby reduce the effective 
diffusion coefficient, resulting in a reduced gamma value. Additionally, any alteration to the 
biocompatible coating, and therefore a change in the adsorption properties of the bead itself, may 
have conflicting results for capture.  In order to fully account for these differences in future 
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experiments, the new lot of beads will now be considered the baseline polymer and all other 
capture experiments will be compared to this lot.   
 
Table 3: Comparison of gamma (Γi) values for IL-6, TNF, and IL-10 in lot #101003 and 
#070907/071007 in buffer 
 
 101003 070907/071007 p value 
IL-6 1.00E-4 1.76E-4 <0.01 
TNF 7.16E-5 4.30E-5 <0.001 
IL-10 5.65E-4 1.86E-5 <0.05 
 
3.2.2 Capture of additional cytokines in buffer 
As previously mentioned, sepsis is characterized by the release of multiple cytokines.  In 
addition to the three main cytokines of interest in this thesis, removal kinetics of “secondary” 
cytokines such as IL-1α, IL-1 receptor antagonist (IL-1RA), HMG-B1, and IL-8 were also 
briefly studied and the results for capture of these cytokines in buffer are detailed below. 
IL-1α is synthesized as a 31kDa precursor that is then cleaved into proteins of 17 kDa, 
secreted by activated monocytes, macrophages, lymphocytes, astrocutes, and endothelial cells in 
response to infection or inflammation.  It induces fever, sleep, neutrophilia or neutropenia, and 
hypertension.  In severe sepsis, the presence of TNF along with IL-1α has been shown to cause 
hypotension and shock and have a negative inotropic effect [16, 50].  Polymorphonuclear 
leukocytes are responsible for the production of IL-1 RA, a 17 kDa  inhibitor of IL-1α.  IL-1 RA 
binds to both forms of IL-1 (α and β) and blocks the binding of IL-1 to its receptor, blocking the 
inflammatory response both in vitro and in vivo [16]. 
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Figure 17 shows IL-1α (left) and IL-1RA (right) capture data in both lots of beads.  Here, 
the average Γi value obtained over two trials was 1.25E-3 ± 8.78E-6 cm2⋅mL⋅min-1⋅g-1, the largest 
Γi value seen so far in capture results. Total cytokine reduction was approximately 100%, 
indicating complete removal of the circulating cytokine from the system before the first 60 
minutes of recirculation were completed.  Our hypothesis for such fast and complete removal is 
based upon both the size of IL-1α (17 kDa).  A smaller cytokine such as IL-1α would more 
easily diffuse further into the pores of the CytoSorb polymer, increasing the apparent surface 
area of the beads and increasing the capture rate.  Additionally, any relative differences in the 
structure or charge of one cytokine compared to another would change the relative affinity of 
that protein for the bead, Ki. These differences, then, would change the capture rate and Γi value, 
which is based on individual cytokine affinities for a particular polymer. 
For IL-1RA, the average Γ i value obtained over two trials was 2.67E-3 ± 9.2E-5 
cm2⋅mL⋅min-1⋅g-1.  Total cytokine removal was approximately 100%, indicating complete 
removal of the circulating cytokine from the system before the first 30 minutes of recirculation 
were completed.  Similarly to IL-1α, IL-1RA is a small cytokine (17 kDa) that presents a larger 
effective diffusion coefficient in our mathematical modeling, increasing the gamma value.  
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Figure 17: IL-1α (left) and IL-1RA (right) capture data and model fits for buffer 
 
High mobility group-box 1 (HMG-B1) is a more recently discovered inflammatory cytokine 
produced in patients with sepsis and is secreted by macrophages.  The timecourse of HMGB1 is 
different from that of other cytokines such as TNF since the rise in concentration occurs much 
later at 16 hours after LPS stimulation, compared to 1-1.5 hours for TNF [51]. 
Finally, IL-8 is a 10 kDa chemotatic and activating agent for neutrophils and T cells that 
is secreted by activated macrophages, monocytes, and Kupffer cells in response to infection.  IL-
8 also causes degranulation of neutrophils specific granules as well as induces expression of cell 
adhesion molecules and angiogenic [52].  Capture data for these four cytokines in the new bead 
lot for both buffer and serum are as follows. 
Figure 18 shows HMG-B1 (left) and IL-8 (right) capture data in both lots of beads.  For 
HMG-B1 (left), error bars indicate error associated with ELISA results for the one trial complete 
with the Γi value of 9.32E-5 cm2⋅mL⋅min-1⋅g-1.  Total cytokine removal was approximately 90%.  
Only one trial of HMG-B1 capture was completed due to cost of the protein as well as the 
immunoassay kit (Shina-Test Co., LTD, Shanghai), a special order. 
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Figure 18: HMGB1 (left) and IL-8 (right) capture data and model fits for buffer 
 
For IL-8, shown in the right panel of Figure 18 above, the average Γ i value obtained over two 
trials was 6.67E-4 ± 2.25E-5 cm2⋅mL⋅min-1⋅g-1.  Total cytokine reduction was approximately 
100%, indicating complete removal of the circulating cytokine from the system before the first 
120 minutes of recirculation were completed.  Similarly to IL-1α, IL-8 is a small cytokine, 
however, at 10 kDa it is actually quite a bit smaller and removal was less than expected if 
molecular weight was the only consideration.  Here, our hypothesis was that relative protein 
structure as well as relative protein affinity for the beads has some effect on capture rates and Γi 
values.  This hypothesis  is supported by similar studies on IL-8 removal by adsorptive sorbents 
where differences in adsorption were not accounted for solely based on molecular weight and 
relative affinity of the chemokine was thought to contribute to the effect [53]. 
3.2.3 Capture of test cytokines in serum 
Once again increasing the complexity of the suspension, seven cytokines were individually 
spiked into horse serum and recirculation experiments were completed.  Figure 19 shows IL-6 
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capture data for both lots of beads in serum.  The average Γi value obtained over three trials was 
5.08E-5 ± 4.2E-6 cm2⋅mL⋅min-1⋅g-1. This value was statistically different from the Γi value of IL-
6 capture in serum for the old lot of beads (1.05E-4 cm2⋅mL⋅min-1⋅g-1, p<0.02) and was also 
statistically different from the Γ i value of capture in buffer for the same lot (1.76E-4 
cm2⋅mL⋅min-1⋅g-1, p<0.001). Total cytokine removal was approximately 87%, a decrease of 
almost 5% compared to the previous lot of beads. 
 
 
Figure 19: IL-6 capture data and model fits for both bead lots in serum 
 
TNF capture results for both lots of beads in serum are shown in Figure 20.  The average Γi value 
obtained over three trials was 4.53E-6 ± 6.4E-7 cm2⋅mL⋅min-1⋅g-1 and was statistically different 
from the Γ i value of TNF capture in the old lot of beads (1.04E-5 cm2⋅mL⋅min-1⋅g-1, p<0.01).  
This value was also statistically different from the Γ i value of capture in buffer for the same lot 
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(3.72E-5 cm2⋅mL⋅min-1⋅g-1, p<0.001). Total cytokine removal was approximately 55%, a 
decrease of more than 10% compared to the previous lot of beads. 
 
 
Figure 20: TNF capture data and model fits for both bead lots in serum 
 
Figure 21 shows IL-10 capture data for both lots of beads in serum.  The average Γ i value 
obtained over three trials was 2.25E-5 ± 2.0E-6 cm2⋅mL⋅min-1⋅g-1.  This value was statistically 
different from the Γ i value of TNF capture in the old lot of beads (1.04E-5 cm2⋅mL⋅min-1⋅g-1, 
p<0.01) and was not statistically different from the Γi value of capture in buffer for the same lot 
(1.96E-5 cm2⋅mL⋅min-1⋅g-1, p=0.10).  Total cytokine reduction was approximately 85%, a 
decrease of almost 5% compared to the previous lot of beads. 
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Figure 21: IL-10 capture data and model fits for both bead lots in serum 
 
Summary of of Γi values for lot #101003 and #070907/071007 is shown in Table 4 below. These 
results clearly indicate that there is a significant difference in capture rates between the two bead 
lots with p-values for each comparison less than 0.05.  In contrast to capture in buffer, all three 
cytokine captures in serum were consistently slower in the new bead lot.  Similarly to capture in 
buffer, we hypothesized that differences in capture rates were attributed to possible differences in 
polymer lot characteristics.  For example, slight differences in pore size resulting in smaller 
average pore diameters would reduce the apparent surface area accessed by the cytokines and 
thereby reducing capture rates. Again, in order to fully account for these differences, the new lot 
of beads will now be considered the baseline polymer and all other capture experiments will be 
compared to this lot. 
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Table 4: Comparison of gamma (Γi) values for IL-6, TNF, and IL-10 in lot #101003 and 
#070907/071007 in serum 
 
 101003 070907/071007 p value 
IL-6 1.05E-4 5.08E-5 <0.05 
TNF 1.03E-5 4.52E-6 <0.001 
IL-10 4.12E-5 2.25E-5 <0.001 
 
3.2.4 Capture of additional cytokines in serum 
For the secondary cytokine data, capture was completed for IL-1α, IL-1RA, HMG-B1, and IL-8 
in serum for the new bead lot.  Figure 22, below, shows capture data for IL-1α (left) and IL-1RA 
(right) in serum for both bead lots. The average Γ i value for IL-1α obtained over two trials was 
3.58E-4 ± 1.8E-4 cm2⋅mL⋅min-1⋅g-1.  This value was statistically different from the Γi value of IL-
1α capture in buffer for the same lot of beads (1.25E-3 cm2⋅mL⋅min-1⋅g-1, p<0.05).  Total 
cytokine removal was approximately 90% over a four hour recirculation experiment, a decrease 
of almost 10% compared to capture in buffer, which showed 100% removal in the first 60 
minutes. 
For capture of IL-1RA in serum for both bead lots, the average Γi value obtained over two 
trials was 8.49E-4 ± 2.9E-5 cm2⋅mL⋅min-1⋅g-1.  This value was statistically different from the Γ i 
value of IL-1RA capture in buffer for the same lot of beads (2.66E-3 cm2⋅mL⋅min-1⋅g-1, p<0.001).  
Total cytokine removal was approximately 90% ninety minutes into the recirculation experiment.  
This reduction was not as fast as capture in buffer, which had complete removal in less than 30 
minutes. 
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Figure 22: IL-1α (left) and IL-1RA (right) capture data and model fits for serum and 
buffer 
 
Capture data for HMG-B1 (left) and IL-8 (right) in serum for both bead lots is shown in Figure 
23.  The Γi value obtained for one trial of HMG-B1 capture was 1.57E-5 cm2⋅mL⋅min-1⋅g-1, a 
value almost six times less than that for capture in buffer.  Total cytokine removal was 
approximately 80% over the course of the four hour recirculation experiment, an increase of over 
10% compared to capture in buffer. 
 
 
Figure 23: HMG-B1 (left) and IL-8 (right) capture data and model fits for serum and 
buffer 
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Finally, for the results of IL-8 capture in the new bead lot, the average Γi value obtained over two 
trials was 5.41E-4 ± 9.4E-5 cm2⋅mL⋅min-1⋅g-1.  This value was not statistically different from the 
Γi value of IL-8 capture in buffer for the same lot of beads (6.65E-4 cm2⋅mL⋅min-1⋅g-1, p=0.55).  
Total cytokine reduction was increased to approximately 100%, indicating complete removal of 
the circulating cytokine from the system before the first 120 minutes of recirculation were 
completed.  This result was the same as that in buffer. 
 In conclusion, for CytoSorb lot #070907/071007, differences in capture between buffer 
and serum are more complex that those found in the original polymer.  There was, specifically, 
an increase in capture rate of IL-6 in buffer and decrease in capture rate for both TNF and IL-10 
in buffer between the new and old lots while capture rates of all three cytokines decreased in 
serum.  These differences, hypothesized to be the result of changes in manufacturing and 
polymer characteristics, will need to be taken into account for future experimentation and 
mathematical modeling.  Baseline capture for the four additional cytokines (IL-1α, IL-1RA, 
HMG-B1, and IL-8) will be advantageous since these new adsorption profiles will be useful in 
both the validation of our in-house model as well as calibration of systems model for sepsis. 
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4.0  SMALL BEAD POLYMER 
In addition to larger diameter polymer, Cytosorbents, Inc., (Monmouth Junction, NJ) also 
provided polymer lots of smaller radii:  WTY-076-44 (58.1 µm), WTY-076-135S (46.4 µm), and 
WTY-076-141S (42.09 µm).  The smaller radius of a bead used in hemoadsorption presents a 
greater available surface area to cytokines in suspension, which in turn increases capture rates.  
This would be advantageous in a hemoadsorption device since increasing available surface area 
as well as capture rates could aid in reducing the length of time the device must be used 
clinically.  Reducing the time used clinically would also reduce risks associated with prolong 
exposure such as activation of complement and the coagulation pathways which are major 
concerns in other purification techniques such as hemodialysis [54, 55]. A summary each of the 
bead lots used in this thesis can be found below in Table 5. 
This chapter focuses on the characterization of the smaller diameter polymer.  We 
hypothesize that small diameter polymer will result in significantly improved cytokine capture 
for all three of the main cytokines of interest.  However, during biocompatibility experiments 
done by the Wagner laboratory, concern arose over the high rates of hemolysis with the smaller 
beads.  The small beads, with greater surface area, are able to remove cytokines much faster; 
however, due to their small size, red blood cells are exposed to much higher shear stresses in 
devices filled with small beads [56].  High rates of hemolysis would be detrimental in clinical 
use, rendering the beads nonbiocompatible.  For this reason, most devices that use sorbent such 
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as beads require a diameter of 100 µm or else a plasma filter must be used to separate the blood 
components to eliminate contact between red blood cells and polymer.  In order to use the 
smaller diameter CytoSorb™ polymer, then, a re-design of the CAD is necessary to address 
these issues. This device, after the proper evaluative tests described in section 4.4, was 
characterized for IL-6, TNF, IL-10, IL-1α, and IL-1RA in serum.  All of the data obtained in this 
chapter for the main cytokines of interest was then compared to baseline capture described in 
Chapter 3.0 using the larger diameter polymer and also compared to capture in the CAD with 
small diameter polymer.  
 
Table 5:  Summary of bead lots used in this study 
Lot # Radius (µm) Description 
101003 284.1 Previous baseline lot 
070907 266.58 Baseline lot 
WTY-076-44 58.1 Small bead 
WTY-076-135S 46.4 Small bead 
WTY-076-141S 42.09 Small bead 
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4.1 reCAD DESIGN AND FABRICATION 
4.1.1 Design 
In order to reduce the shear stress in the device we re-engineered the CAD. Using the Ergun 
equation for fluid flow in a packed bed 
 
    (4) 
 
we calculated the theoretical pressure drop in a packed bed where  is the pressure drop, L is 
the length of the bed, µ is the viscosity of the solution, Vs is the superficial velocity, Dp is the 
diameter of the resin, and ε is the void fraction of the bed.  Using this pressure drop we were able 
to calculate the theoretical shear stress as: 
 
     (5) 
where τ	  is	  the	  shear stress, Aε is the area of void space in the column, and Sp is the surface area 
of the particles [57].  With these equations, we then modified existing parameters for bed length 
and diameter of the column to obtain a shear stress below the hemolysis threshold.   Figure 24, a 
shear stress versus time plot [57], shows the results of plotting the theoretical data for large and 
small beads in the CAD as well as small beads in the reCAD and experimental data for the 
reCAD.  The lines indicate cell trauma limits induced by shear, the material, and hemolysis.  The 
ideal device would induce shear stresses below the hemolysis line (small black dash). From the 
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plot below, small beads in the CAD produce shear above the hemolysis line (teal); however, re-
engineering the device to modify the dimensions of the packed bed reduces the shear stress over 
exposure time to a more acceptable level (pink). 
 
Figure 24: Plot of shear stress versus exposure time to determine hemolytic tendencies of our 
devices [57] 
 
Therefore, to reduce shear, we designed a device that had a shorter bead bed length and wider 
bed width, as seen in Figure 25.  The dimensions of packed bead bed in the re-engineered CAD, 
or reCAD, are 1/4” in length and 1” wide, which theoretically allows flow in the device to be 
within an acceptable range for shear stress. Table 6 shows a comparison of design parameters for 
both the CAD and reCAD. 
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Figure 25: reCAD 
 
Table 6:  Comparison of design parameters for CAD and reCAD 
 CAD reCAD 
Bead length 1 inch 0.25 inch 
Bed width 0.31 inch 1 inch 
Mass of beads 1.49 g 2.4 g 
 
4.1.2 Fabrication 
Fabrication of the reCAD required machining and assembly by the laboratory fabricator, Mr. 
Brian Frankowski.  The clear end of the reCAD is a 1.13” long section of the end of a BD 30 mL 
Luer-Lok disposable syringe, machined to the correct dimensions.  The opaque end of the 
reCAD is machined Delrin with a female luer-to-thread secured with adhesive.  To keep the 
beads packed within the device, a 13/16” in diameter 36 µm polyurethane mesh (Small Parts, 
Inc., Miramar, FL) disc is glued into the clear end cap suing a small amount of clear RTV 
silicone adhesive sealant (Permatex, Solon, OH).  A 9/16” in diameter 36 µm polyurethane mesh 
(Small Parts, Inc., Miramar, FL) disc is then glued to the inner side of the Delrin end cap using 
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the same adhesive.  Once completely dried, the CAD is assembled as shown in Figure 26, below, 
with caps screwed onto the ends of the device. 
 
 
 
Figure 26: Schematic of reCAD 
 
To ensure repeatability, devices are weighed before and after packing.  The mass value is then 
compared to a set average mass established in-house, plus or minus one standard deviation, of 
2.4 g ± 0.12 g (2.28 g – 2.52 g).  This is to ensure that all of the cartridges are packed to the same 
weight specification for repeatability. 
4.2 EVALUATIVE TESTING 
After initial testing with the reCAD, especially biocompatibility tests done by our colleagues in 
another lab, it became apparent that settling might become an issue in the device.  Settling, 
caused by nonbuyout beads responding to the pull of gravity, would likely cause shunting in the 
device and nonideal flow through the bead bed.  If shunting were to occur, apparent surface area 
for cytokine adsorption would be limited thereby reducing capture rates and creating an 
inefficient device.  Due to these concerns, then, the proper orientation for use needed to be 
Delrin end Modified syringe end 
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determined for the reCAD.  To do this, both pressure drop testing and flow visualization were 
completed on several devices.  Pressure drop testing was used to determine if shunting was 
occurring; however, a negligible drop across the reCAD (similar to results with the original 
CAD), made this test ineffective.  Therefore, flow visualization using a dye was used to 
determine flow patterns in several orientations of the reCAD. 
4.2.1 Flow visualization  
Flow visualization was used as the most basic method to determine flow patterns in the newly 
engineered reCAD.  Three sets of flow visualization experiments were completed.  In the first, 
the reCAD was placed in a horizontal position with the opaque end cap as the inlet.  The second 
study also had the device placed horizontally, but with the clear end as the inlet.  Finally, the 
reCAD was oriented vertically with the clear end on the bottom as the inlet.   
To do these experiments, a freshly made reCAD was attached to 2 5” pieces of 3/32” ID 
Tygon tubing (OD 5/32”) with a male and female 3/32” to barb leur.   The device was clamped 
and placed in the desired orienation using a three-prong clamp and ring stand.  A syringe pump 
with a 50 mL BD syringe was attached to a three-way stopcock that was in turn connected to the 
tubing leading to the reCAD.  The stopcock was used as a way to introduce a bolus of dye into 
the stream of clear distilled water.  To do this, a small volume of distilled water was dyed using 
Evens Blue (Sigma) and taken up in a 5 mL BD syringe.  Once the reCAD was completely 
primed, the pump was turned off, the syringe was loaded into the stopcock, and the dye injected.  
The syringe pump was then quickly turned back on and the flow pattern of the dye was 
visualized and documented by digital camera. 
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The result of the first test is shown in Figure 27, below.  In this test, the opaque end, with 
the smaller inlet entrance (compared to the clear end) was the inlet and the device was placed 
horizontally.  From the picture, the area of blue appearing along the bottom of the device is 
easily identifiable.  This flow represents a nonideal pattern since it is shows perfusion through 
less than 50% of the available area.  Similarly, the second test, with the clear end as the inlet, had 
similar flow pattern through the device, with the blue dye flowing only through the bed along the 
bottom of the device.  We hypothesized that since the packed bed is in reality in slurry form, the 
nonbuoyant beads settled to the bottom of the device and affect the flow through the device.  In 
order to correct this, the final set of experiments involved reorienting the device to a vertical 
position. 
 
 
Figure 27: Flow visualization test results for horizontal orientation.  Note the area of dye at the 
bottom of the device due to settling, a nonideal flow pattern (red arrow). 
 
The third set of tests with the reCAD in the vertical position with the clear end as the inlet on the 
bottom yielded the best results but with a slight modification.  As shown in the upper panel of 
Figure 28, the vertically oriented reCAD continued to show nonideal flow in that only half the 
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device had dye perfusing through it.  We hypothesized that since this device was resting on its 
side prior to testing, the beads had enough time to settle.  A series of flow visualization 
experiments testing this hypothesis found it to be true.  The final experiment, results of which are 
shown in the lower panel of Figure 28, involved keeping the device in an upright position prior 
to testing to ensure an evenly distributed bead bed.  The flow in this device was evenly 
distributed as indicated by the blue dye.  In order to obtain the best possible flow, the last 
recommendation made included perfusing the device with the clear end as the inlet, since this 
end was fabricated with a more gradual and wider entrance opening for fluid flow.   
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Figure 28:  Flow visualization test results for horizontal orientation.  First reCAD (upper panel) 
was resting horizontally before testing (red arrow indicates nonideal flow pattern) while second 
reCAD (lower panel) was placed in an upright position has more evenly distributed flow. 
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4.3 reCAD CAPTURE EXPERIMENTS 
4.3.1 Materials and methods 
In general, materials and methods for capture experiments serum with the small bead polymer in 
the newly engineered reCAD were done exactly as described in section 2.2.1 except reCADs 
were placed in a vertical orientation with the clear end as the bottom. Fabricated reCADs were 
filled with CytoSorbTM polymer lot WTY-076-44 (58.1 µm), WTY-076-135S (46.4 µm), or 
WTY-076-141S (42.09 µm) provided by Cytosorbents, Inc. (Monmouth Junction, NJ).  
4.3.2 Statistical analysis 
To compare data sets for the two bead lots for each cytokines, the average Γi value and standard 
deviation was calculated for each set of experiments, with n=3 unless otherwise stated.  Γi values 
were then compared using an independent t-test with p < 0.05 considered significant and 
indicating a difference in the mean Γi values. 
4.4 RESULTS AND DISCUSSION 
4.4.1 Capture of test cytokines in serum 
Results of IL-6 capture in the reCAD using the small bead polymer are shown in Figure 29. The 
average Γ i value obtained over three trials was 9.08E-6 ± 6.5E-6 cm2⋅mL⋅min-1⋅g-1.  This value 
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was statistically different from the Γi value of IL-6 capture in what we refer to as the baseline lot, 
lot #070907, with a larger radius of 266.58 µm (5.08E-5 cm2⋅mL⋅min-1⋅g-1, p<0.001).  Total 
cytokine removal using the small bead lot was more than 90%, the same as that in the larger 
polymer over the entire four hour experiment.  Unfortunately, the fit of the model for the smaller 
polymer is poor for timepoints beyond 60 minutes.  This deviation occurred after 90% of the 
cytokine was removed; however, Γ i values were not statistically the same between small bead 
and baseline polymer.  A change to the current model could be implemented to correct for the 
poor model fits seen in IL-6 capture as well as IL-10 capture, detailed later in this section. A 
properly fit model would then produce the expected Γi value, one that is statistically the same as 
the baseline polymer. 
 
 
Figure 29: IL-6 capture data and model fits for serum 
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As a first step towards modifying the model and correcting the fits, a modification was made to 
the current model to include another fitting parameter, Cinf, or concentration at infinity, so that 
later timepoints fit to the model more suitably.  Incorporation of this parameter into the 
MATLAB™ integration and fitting programs is shown in Appendix A.2 and 
the results for IL-6 are shown in Figure 30, below.  The new model fit produced a Γ i value of 
3.40E-5 ± 6.7E-6 cm2⋅mL⋅min-1⋅g-1  (R2 = 0.99) which was not significantly different from 
baseline capture (5.08E-5 cm2⋅mL⋅min-1⋅g-1, p=0.077).  These results indicate that the modified 
model is able to properly fit the experimental data and produce an expected Γi value.  This 
modified model will be used to fit other capture data that deviates from the original model to a 
specified extent.  Deviations will be quantified using R2, with any R2 values less than 0.95 
resulting in the use of the modified model.  This R2 value was determined empirically by 
comparing results of several capture experiments fit to the original model and the modified 
model. 
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Figure 30:  Modified model fit for IL-6 capture with small bead polymer 
 
For TNF capture in the reCAD, shown in Figure 31, the average Γ i value obtained over three 
trials was 6.47E-6 ± 4.7E-6 cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the 
Γi value of TNF capture in the larger polymer, lot #070907 (4.528E-6 cm2⋅mL⋅min-1⋅g-1, 
p=0.513). Total cytokine reduction using the small bead lot in the reCAD was approximately 
94%.  This value was significantly improved over that of the baseline polymer with only 55% 
total removal.  The increase in removal was attributed to increased apparent surface area 
available to the TNF molecules for adsorption.  Unlike IL-6, model fits for TNF do not deviate 
far from the experimental data with R2 values greater than 0,98; therefore, TNF data was not fit 
to the modified model. 
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Figure 31: TNF capture data and model fits for serum 
 
For IL-10 capture in the reCAD, shown in Figure 32, the modified model gave a Γ i value of 
1.38E-4 ± 1.6E-4 cm2⋅mL⋅min-1⋅g-1. This value was also not statistically different from the Γ i 
value of IL-10 capture in lot #070907 (2.25E-5 cm2⋅mL⋅min-1⋅g-1, p=0.369).   Total cytokine 
reduction using the small bead lot in the reCAD was approximately 97%, an almost 10% 
increase in removal compared to the larger diameter bead lot. 
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Figure 32: IL-10 capture data and model fits for serum 
 
IL-1α (left) and IL-1RA (right) captures in the reCAD are shown in Figure 33, below.  The 
average Γi value for IL-1α over three trials could not be obtained using our mathematical model 
and it was concluded that the resolution within the first three timepoints was not great enough for 
MATLAB to run the program correctly.  Total cytokine reduction using the small bead lot in the 
reCAD was 100% within the first 60 minutes of the experiment compared to 90% over the 
course of the experiment with the larger diameter polymer in the CAD.  Average IL-1RA Γ i 
value for three trials was 8.03E-6 ± 7.9E-5 cm2⋅mL⋅min-1⋅g-1. This value was statistically 
different from the Γ i value of IL-1RA capture in lot #070907 (8.49E-4 cm2⋅mL⋅min-1⋅g-1, 
p<0.001).  Total IL-1RA removal was 100% within the first ninety minutes of the capture 
experiment, the same as the baseline polymer in the CAD.  Our hypothesis for such fast and 
complete removal is based upon both the size of IL-1α and IL-1RA (17 kDa).  A smaller 
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cytokine such as IL-1α or IL-1RA would more easily diffuse further into the pores of the smaller 
CytoSorb polymer, further increasing the apparent surface area of the beads and increasing the 
capture rate over that of the larger polymer. 
 
 
Figure 33: IL-1α (left) and IL-1RA (right) capture data and model fits for serum 
 
In conclusion, we were able to engineer and develop a device for use with small diameter 
polymer that has reduced shear stress compared to our original CAD.   Furthermore, capture of 
IL-6, TNF, and IL-10 in lots of smaller diameter polymer in the newly re-engineered CAD, or 
reCAD, results in significantly increased total removal as well as significantly decreased times to 
total removal compared to the baseline polymer in the CAD.   Baseline capture for the two 
additional cytokines (IL-1α and IL-1RA) were beneficial given that these new adsorption 
profiles will be useful in the calibration of both our in-house model as well as the systems model 
for sepsis for the reCAD.  
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The introduction of the modified model was also advantageous in this part of the study, 
producing model fits with higher R2 values and producing Γi values that were statistically the 
same as capture in the CAD, as summarized in Table 7, below.   
 
Table 7: Gamma (Γi) values for IL-6, TNF, and IL-10 capture using small diameter polymer in 
the reCAD 
 
 CAD Small bead 
reCAD 
p value Modified 
code 
p value 
IL-6 5.08E-5 9.08E-6 <0.001 3.40E-5 =0.310 
TNF 4.52E-6 6.47E-6 =0.513 - - 
IL-10 2.25E-5 1.59E-5 =0.483 1.38E-4 =0.369 
 
4.5 CAD CAPTURE EXPERIMENTS 
In order to ensure that flow within the reCAD was ideal and uniform, testing of the small 
polymer in the original CAD was completed for IL-6, TNF, and IL-10.  Using these results, we 
were able to determine that the capture rates using the CAD and reCAD were statistically the 
same, indicating that flow within the reCAD was sufficient.  The results of this work are 
presented in the following sections. 
4.5.1 Materials and methods 
In general, materials and methods for fabrication and capture experiments in serum only with the 
small bead polymer were done exactly as described in sections 2.1.2 and 2.2.1.   Fabricated 
CADs, however, were filled with CytoSorbTM polymer lot WTY-076-44 (58.1 µm), WTY-076-
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135S (46.4 µm), or WTY-076-141S (42.09 µm) provided by Cytosorbents, Inc. (Monmouth 
Junction, NJ).  These smaller diameter beads required the use of a finer mesh screen for the 
filters, a 36 µm polyurethane mesh (Small Parts, Inc., Miramar, FL), instead of the larger 250 µm 
polyurethane mesh (Small Parts, Inc., Miramar, FL). 
4.5.2 Statistical analysis 
To compare data sets for the two bead lots for each cytokines, the average Γi value and standard 
deviation was calculated for each set of experiments, with n=3 unless otherwise stated.  Γi values 
were then compared using an independent t-test with p < 0.05 considered significant and 
indicating a difference in the mean Γi values. 
4.6 RESULTS AND DISCUSSION 
4.6.1 Capture of test cytokines in serum 
Results of IL-6 in the small bead polymer are shown in Figure 34. The modified model fit 
produced a Γ i value of 2.60E-4 ± 2.5E-4 cm2⋅mL⋅min-1⋅g-1 which was not significantly different 
from baseline capture (5.08E-5 cm2⋅mL⋅min-1⋅g-1, p=0.225) and was not statistically different 
from small bead polymer in the reCAD (9.08E-6 cm2⋅mL⋅min-1⋅g-1, p=0.490). Total cytokine 
removal using the small bead lot was more than 90%, the same as that in the smaller polymer in 
the reCAD over the entire four hour experiment. 
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Figure 34: IL-6 capture data and model fits for serum 
 
Results of TNF in the small bead polymer are shown in Figure 35. The average Γi value obtained 
over three trials was 4.77E-6 ± 1.0E-6 cm2⋅mL⋅min-1⋅g-1.  This value was not statistically 
different from the Γ i value of TNF capture in the larger polymer, lot #070907 (4.53E-6 
cm2⋅mL⋅min-1⋅g-1, p=0.749) and was not statistically different from capture with the small bead 
in the reCAD (6.47E-6 cm2⋅mL⋅min-1⋅g-1, p=0.570).  Total cytokine removal using the small bead 
lot was increased to more than 90%, which is a significant increase compared to a 55% total 
removal in the larger diameter beads yet was the same as removal in the reCAD.  This increase 
in removal was attributed to increased apparent surface area available to the TNF molecules for 
adsorption.  Unlike IL-6, model fits for TNF do not deviate far from the experimental data; 
therefore, TNF data was not fit to the modified model. 
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Figure 35: TNF capture data and model fits for serum 
 
Results of IL-10 in the small bead polymer are shown in Figure 36. Producing a better fit, the 
modified model gave a Γi value of 3.39E-5 ± 1.1E-5 cm2⋅mL⋅min-1⋅g-1. This value was not 
statistically different from the Γi value of IL-10 capture in lot #070907 (2.25E-5 cm2⋅mL⋅min-1⋅g-
1, p=0.159) and was not statistically different from small bead polymer in the reCAD (1.38E-5 
cm2⋅mL⋅min-1⋅g-1, p=0.435).  Total cytokine removal using the small bead lot was approximately 
94%, an almost 10% increase in removal compared to the larger diameter bead lot and the same 
as in the reCAD. 
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Figure 36: IL-10 capture data and model fits for serum 
 
In conclusion, capture of IL-6, TNF, and IL-10 in lots of smaller diameter polymer in both the 
CAD and reCAD results in significantly increased total removal as well as significantly 
decreased times to total removal.  Since the gamma values for capture using the small polymer 
were statistically the same, the flow within the reCAD is assumed to be ideal and uniform.  
Therefore, the recommendations established from flow visualization in section 4.2.1 are 
validated and should be followed when testing using the reCAD. 
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5.0  CAPTURE IN RED BLOOD CELL SUSPENSIONS 
The previous chapters in this work are beneficial for the development and optimization of a new 
sorbent material by establishing baseline capture rates for main cytokines of interest in the 
simplest buffer suspensions.  Although extremely useful in our preliminary work, capture 
profiles of the cytokines of interest must also be done in more complex suspensions such as 
whole blood.  This work will be important not only for our understanding of capture profiles in 
whole blood, for which the device will ultimately be used, but also for the calibration and 
optimization of the systems model of sepsis being developed by our colleagues.  In this chapter, 
we wanted to test whether the presence of red blood cells, plasma components, and white blood 
cells would have an effect on capture. These final sets of experiments involve cytokines spiked 
into several different red blood cell suspensions.  We first hypothesized that the presence of red 
blood cells in a buffer suspension would not have any effect on capture rates when compared to 
baseline capture in buffer.  Furthermore, we hypothesized that the presence of plasma and serum 
components such as cytokine receptors, complement component, and growth factors would have 
no effect on capture rates when compared to baseline capture in serum.  Finally, we hypothesized 
that capture of cytokine in healthy human whole blood would not be changed when compared to 
baseline capture in human plasma.  To test these hypotheses, we first resuspended washed human 
red blood cells obtained from healthy volunteers in buffer spiked with the cytokine of interest.  
Next, we performed a set of capture experiments for red blood cells resuspended in fresh human 
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plasma spiked with cytokines.  Finally, we completed our testing with capture of human whole 
blood spiked with cytokines.  All of these data sets were completed for the three main cytokines 
of interest: IL-6, TNF, and IL-10.  Additional controls were also performed and will be discussed 
in the appropriate sections. 
Collection data in red blood cell suspensions becomes important not only for the 
validation of our mathematical model, but also to investigate any possible interactions the 
presence of red blood cells, white blood cells, and plasma components may have on capture 
rates.  Although these additional complexities are not accounted for in our in-house mathematical 
model, our colleagues developing a systems model of sepsis and treatment with our device 
would benefit from such data for calibration. 
5.1 CAPTURE EXPERIMENTS 
5.1.1 Materials and methods 
In general, recirculation experiments in red blood cell suspensions were done as follows.  With 
approval of the University of Pittsburgh Institutional Review Board (IRB), 100 mL of fresh 
human whole blood was obtained from healthy, consenting volunteers and collected into 
heparinated tubes.  The blood was then centrifuged and the plasma pipetted and discarded or 
collected depending upon the experiment performed.  Fresh PBS (pH 7.4) was added to the tubes 
in a 3:1 ratio to red blood cells.  Cells were gently mixed to resuspend them and then centrifuged.  
Two more washing steps were then completed. 
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Once the red blood cells were washed, the suspension of choice (buffer or human plasma) 
was prepared and spiked with the cytokine of interest for a final concentration of 1000-5000 
pg/mL.  For each reservoir, 9 mL of spiked buffer or plasma was added to 6 mL of red blood 
cells and gently mixed.  The suspension was then placed on a stir plate and mixed well before the 
start of the experiment. 
A fabricated CAD was then filled with CytoSorbTM polymer lot #070907 from 
Cytosorbents, Inc. (Monmouth Junction, NJ).  The mass of the device before and after filling was 
measured and recorded in order to ensure repeatability between trials, as described in section 
2.1.2.  To connect the CAD to tubing, a female 3/32” leur lock with a 5” piece of 3/32” ID (5/32” 
OD) Tygon tubing and a male 3/32” leur lock with a 5” piece of 3/32” ID (5/32” OD) Tygon 
tubing were connected to the appropriate ends of the CAD.  This was then connected to a 3/32” 
fitting for a low-flow peristaltic pump (Fisher Scientific, Waltham, MA) and the other end of the 
fitting was connected to a 10” piece of 3/32” ID (5/32” OD) Tygon tubing, see Figure 37, below, 
for an actual experimental set-up. 
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Figure 37: Experimental set-up of red blood cell suspension recirculation through a CAD 
 
Once the tubing was fitted into the pump, the inlet end was placed in a beaker containing 
approximately 20 mL of PBS (pH 7.4) and the tubing and CAD were primed for at least 30 
minutes.  During this time, the pump was calibrated to the appropriate flow rate of 1.33 mL/min, 
unless otherwise stated.  Note the increased flow rate due to scaling up by hematocrit (40%).  In 
order for these experiments to be compared to those of the previous chapters, the flow rate and 
reservoir volume were scaled by hematocrit so that “plasma” flow rate, Qp, and “plasma” 
reservoir volume, Vp, remained 0.8 mL/min and 8 mL, respectively.   This is because cytokines 
are present only in the plasma phase, therefore Qp and Vp must be uniform. Qp and Vp  are 
defined as: 
 
Qp = (1-HCT)Q    (6) 
Peristaltic pump 
CAD 
Reservoir  
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where HCT is % hematocirt and Q is the total flow rate and 
 
Vp = (1-HCT)V     (7) 
 
where HCT is % hematocirt and V is the total reservoir volume. 
Once the tubing and CAD were fully primed with PBS, the inlet end of the tubing was 
removed from the reservoir to create approximately a 3” bubble of air in the tubing.  The tubing 
inlet was then placed in the reservoir containing the suspension of interest. The experiment 
began when the first drop of the suspension entered the reservoir from the outlet end of the 
tubing.  Sampling was done by pipetting 500 µL volumes from the reservoir and transferring to a 
labeled eppendorf tube for time points: 0 (baseline, before recirculation begins), 15, 30, 60, 90, 
120, 180, and 240 minutes for all capture experiments.  Samples were then centrifuged and the 
supernatant frozen at -80oC until they could be assayed. All samples were assayed using a solid 
phase sandwich Enzyme Linked Immunosorbent Assay (ELISA) purchased commercially, 
according to the instructions from the manufacturer (Invitrogen, Camarillo, CA). 
During experimentation with whole blood in section 5.4.1, decreased capture rates 
observed were hypothesized to be the result of either the production of cytokines and/or the 
activation of white blood cells.  The activation of white blood cells and platelets may be caused 
by the circuit itself, since the reservoir is open to air and not temperature controlled, i.e. kept at 
room temperature and not 37oC.   For the experimental set-up using a blood bag in section 5.4.1 
that addresses the concerns of temperature and open-loop, materials and methods are as follows.  
Whole blood was obtained and spiked as described previously.  The recirculation loop was 
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prepared by connecting the fabricated CAD to a female 3/32” leur lock with a 2” piece of 3/32” 
ID (5/32” OD) Tygon tubing to the inlet side and a three-way stopcock on the outlet side.  The 
short piece of tubing was then connected to a 3/32” fitting for a low-flow peristaltic pump 
(Fisher Scientific, Waltham, MA) and the other port of the stopcock was connected to the tubing 
attached to a blood bag spike, cut to approximately 2”.  The other end of the pump fitting was 
connected to a 4” piece of 3/32” ID (5/32” OD) Tygon tubing which was in turn attached to a 
three-way stopcock and then the tubing attached to the blood bag, a Cyrostore CS 25q 25 mL bag 
from OriGen Biomedical (Austin, TX). The top of the blood bag was folded over and clamped 
off with small binder clips to keep the blood in the main part of the bag.  See Figure 38, below, 
for a schematic of the experimental set-up. 
 
 
 
 
 
 
 
 
Figure 38:  Schematic of a closed-loop capture experiment set-up  
 
To prime and de-air the loop, all tubing and parts were connected and removed from the pump 
head.  With a syringe, 15-20 mL of PBS (pH 7.4) was added to the loop from the stopcock 
connected to the CAD (priming port).  The loop was then re-connected to the pump head and 
Peristaltic pump 
Priming port 
CAD 
Blood bag 
De-airing and  
sampling port 
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allowed to recirculate for 30 minutes.  After 30 minutes, the loop was drained.  With a syringe, 
15 mL of spiked whole blood was slowly introduced into the loop by the priming port (other 
stopcock closed towards blood bag to prevent blood from spilling) ensuring that no bubbles were 
introduced into the blood bag.  To de-air any bubbles that did form, the stopcock connected to 
the CAD was closed and a syringe attached to the de-airing port in the other stopcock to pull the 
air from the blood bag.  When all bubbles were removed, the tubing was reconnected and 
connected to the pump head. The blood bag was placed inside an ISOTEMP 2025 water bath 
(Fisher Scientific, Pittsburgh, PA) to maintain blood temperature at 37oC.  Additionally, the bag 
was hand mixed every 15 minutes to ensure proper mixing. The experiment began as soon as the 
pump was turned on. 
Sampling was done by transferring 500 µL volumes from the sampling port located in the 
stopcock after the blood bag in the loop and transferring to a labeled eppendorf tube for time 
points: 0 (baseline, before recirculation begins), 15, 30, 60, 90, 120, 180, and 240 minutes for all 
capture experiments.  To sample effectively from the blood bag (reservoir), a small volume was 
drawn out of the loop first, then the sample taken, then the small volume was reintroduced.  
Samples were then centrifuged and the supernatant frozen at -80oC until they could be assayed. 
All samples were assayed using a solid phase sandwich Enzyme Linked Immunosorbent Assay 
(ELISA) purchased commercially, according to the instructions from the manufacturer 
(Invitrogen, Camarillo, CA).  
5.1.2 Statistical analysis 
To compare data sets for different cytokines or different suspensions, the average Γi value and 
standard deviation was calculated for each set of experiments, with n=3 unless otherwise stated.  
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Γi values were then compared using an independent t-test with p < 0.05 considered significant 
and indicating a difference in the mean Γi values.   
5.2 CAPTURE OF CYTOKINES OF INTEREST IN RED BLOOD CELLS 
RESUSPENDED IN BUFFER 
5.2.1 Capture of IL-6 in RBC resuspended in buffer  
As a first set of experiments, we wanted to simplify capture in blood as much as possible and 
determined that red blood cells resuspended in buffer would achieve such a goal.  We 
hypothesized that the presence of red blood cells would have no effect on capture rates and as 
shown in Figure 39, our hypothesis proved to be correct.  For IL-6 capture in red blood cells 
resuspended in buffer, the average Γ i value obtained over three trials was 1.56E-4 ± 4.4E-5 
cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the Γ i value of IL-6 capture in 
buffer (1.76E-4 cm2⋅mL⋅min-1⋅g-1, p=0.505).  Total cytokine removal and overall trend of capture 
was exactly as seen in IL-6 capture in only buffer. 
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Figure 39:  IL-6 capture in red blood cells resuspended in buffer 
 
To ensure that no interaction between the red blood cells (or lysate) and IL-6 was taking place, 
two additional controls were also performed.  In the first, IL-6 was spiked into buffer that 
contained lysed red blood cells.  For this experiment, approximately 13 mL of washed red blood 
cells resuspended in buffer (40% HCT) were mechanically lysed with small metal ball bearings 
and then centrifuged.  The supernatant was removed and placed into beakers for a typical 
recirculation experiment.  Results of this experiment are shown in Figure 40 (left).  The average 
Γi value obtained over two trials was 1.43E-4 ± 2.4E-5 cm2⋅mL⋅min-1⋅g-1. This value was not 
statistically different from the Γ i value of IL-6 capture in buffer (1.76E-4 cm2⋅mL⋅min-1⋅g-1, 
p=0.268).  In the second experiment, red blood cells were incubated with spiked buffer for one 
hour on a rocker.  After the incubation, the suspension was centrifuged and the supernautant 
removed and used in a typical recirculation experiment.  Results of this experiment are shown in 
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Figure 40 (right).  The average Γ i value obtained over two trials was 1.23E-4 ± 3.5E-7 
cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the Γ i value of IL-6 capture in 
buffer (1.76E-4 cm2⋅mL⋅min-1⋅g-1, p=0.144).  From these controls, it is clear that there is no 
interaction between the red blood cells and the cytokine.   
 
 
Figure 40:  Lysed red blood cell capture (left) and buffer incubated in red blood cell capture 
(right) controls for red blood cell suspension capture 
 
The next set of experiments included modifying the resevior volume and flow rate to test 
wheather the model was able to predict a change in Γi value associated with not scaling the 
experiment to hematocrit, i.e. having a slower flow rate and reduced reservoir volume.  From 
past validation experiments [46], the model was able to accurately predict changes in flow rate 
and reservoir volume and we hypothesized that the model would perform the same with this 
experiment.  As shown in Figure 41, not scaling the red blood cell experiment does have an 
effect on overall capture trends, causing faster removal.  We hypothesize that this effect is most 
likely due to the decreased reservoir volume, with decreased flow rate having a lesser effect.  
The average Γ i value obtained over three trials was 4.85E-4 ± 1.8E-4 cm2⋅mL⋅min-1⋅g-1. This 
value was not statistically different from the Γ i value of IL-6 capture in buffer (1.76E-4 
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cm2⋅mL⋅min-1⋅g-1, p=0.101).  Therefore, the model was able to predict changes in the model 
regardless of scaling to hematocrit.  
 
 
Figure 41:  IL-6 capture with modified flow rate and reservoir volume to test model validation 
5.2.2 Capture of TNF in RBC resuspended in buffer  
Similarly to capture with IL-6, as a first set of experiments, we wanted to simplify capture in 
blood as much as possible and began experimentation with TNF in red blood cells resuspended 
in buffer.  We hypothesized that the presence of red blood cells would again have no effect on 
capture rates and as shown in Figure 42, our hypothesis proved to be correct.  For TNF capture in 
red blood cells resuspended in buffer, the average Γi value obtained over three trials was 2.38E-5 
± 2.5E-6 cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the Γi value of TNF 
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capture in buffer (3.72E-5 cm2⋅mL⋅min-1⋅g-1, p=0.810).  Total cytokine removal and overall trend 
of capture was exactly as seen in TNF capture in only buffer.  These results indicate that the 
presence of red blood cells alone have no effect on capture of TNF in buffer. 
 
 
Figure 42:  TNF capture in red blood cells resuspended in buffer 
5.2.3 Capture of IL-10 in RBC resuspended in buffer  
To round out our set of experiments of resuspended red blood cells, we finish this section with 
capture of IL-10 in each of the three previously discussed suspensions.  For IL-10 capture in red 
blood cells resuspended in buffer, shown in Figure 43, the average Γ i value obtained over three 
trials was 1.66E-5 ± 3.0E-6 cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the 
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Γi value of IL-10 capture in buffer (5.64E-5 cm2⋅mL⋅min-1⋅g-1, p=0.187).  Total cytokine removal 
and overall trend of capture was exactly as seen in IL-10 capture in buffer only. 
 
 
Figure 43:  IL-10 capture in red blood cells resuspended in buffer 
 
In conclusion, capture of IL-6 in red blood cell suspensions of buffer, as well as controls, were as 
expected, proving that the presence of red blood cells was not significant and had no interaction 
with the beads or IL-6.  Additional experiments in this section included proved that the model 
was valid for capture experiments that were not scaled to hematocrit.  Capture of TNF and IL-10 
in red blood cell suspensions of buffer were both also as expected, proving that the presence of 
red blood cells was not significant and had no interaction with the beads or TNF or IL-10. 
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5.3 CAPTURE OF CYTOKINES OF INTEREST IN RED BLOOD CELLS 
RESUSPENDED IN HUMAN PLASMA 
5.3.1 Capture of IL-6 in RBC resuspended in plasma  
Our second set of experiments included recirculation of IL-6 in human plasma (compared to 
horse serum) as well as human red blood cells resuspended in human plasma.  Here, we wanted 
to add another degree of complexity over simple buffer experiments and test whether the 
presence of human plasma would affect capture similarly to horse serum.  We hypothesized that 
the presence of red blood cells would again have no effect on capture rates between capture in 
horse serum, capture in plasma only, and capture in red blood cells resuspended in plasma.  
However, there would be a difference between capture in plasma-based suspensions and those in 
only buffer.  This reduction in capture rates from buffer to serum would most likely be due to the 
presence of additional components found in serum and plasma suspensions such as cytokine 
receptors, additional larger proteins, complements, etc.   
For these capture experiments, shown in Figure 44, the average Γ i value obtained over 
two trials of IL-6 capture in human plasma was 6.90E-5 ± 4.0E-5 cm2⋅mL⋅min-1⋅g-1. This value 
was not statistically different from the Γ i value of IL-6 capture in horse serum (5.08E-5 
cm2⋅mL⋅min-1⋅g-1, p=0.672) and was statistically different from capture in red blood cells 
resuspended in buffer (1.56E-5 cm2⋅mL⋅min-1⋅g-1, p<0.01). For IL-6 capture in red blood cells 
resuspended in plasma, the average Γ i value obtained over three trials was 3.79E-5 ± 7.1E-6 
cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the Γ i value of IL-6 capture in 
serum (5.80E-5 cm2⋅mL⋅min-1⋅g-1, p=0.060).  Total removal of IL-6 in red blood cells 
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resuspended in plasma was decreased 5% to 93% removal compared to red blood cells 
resuspended in buffer with 97% removal. 
 
 
Figure 44:  IL-6 capture in human plasma and red blood cells resuspended in human plasma 
5.3.2 Capture of TNF in RBC resuspended in plasma  
Our second set of experiments included recirculation of TNF in human plasma (compared to 
horse serum) as well as human red blood cells resuspended in human plasma.  We again 
hypothesized that the presence of red blood cells would again have no effect on capture rates 
between capture in horse serum, capture in plasma only, and capture in red blood cells 
resuspended in plasma.  However, there would be a difference between capture in plasma-based 
suspensions and those in only buffer. 
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For these capture experiments, shown in Figure 45, the average Γ i value obtained over 
two trials of TNF capture in human plasma was 7.69E-6 ± 1.7E-6 cm2⋅mL⋅min-1⋅g-1 and was not 
statistically different from the Γi value of TNF capture in horse serum (4.53E-6 cm2⋅mL⋅min-1⋅g-1, 
p=0.530) and was statistically different from capture in red blood cells resuspended in buffer 
(2.38E-5 cm2⋅mL⋅min-1⋅g-1, p<0.05). For TNF capture in red blood cells resuspended in plasma, 
the average Γi value obtained over three trials was 4.90E-5 ± 4.9E-7 cm2⋅mL⋅min-1⋅g-1. This value 
was not statistically different from the Γ i value of TNF capture in serum (4.52E-6 cm2⋅mL⋅min-
1⋅g-1, p=0.501).  Total reduction of TNF spiked in whole blood was decreased more than 25% to 
56% total removal compared to red blood cells resuspended in buffer with more than 80% 
removal. 
 
 
Figure 45:  TNF capture in human plasma and red blood cells resuspended in human plasma 
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5.3.3 Capture of IL-10 in RBC resuspended in plasma  
For IL-10 capture experiments in plasma and red blood cells resuspended in plasma, shown in 
Figure 46, the average Γ i value obtained over two trials of IL-10 capture in human plasma was 
1.96E-5 ± 6.9E-6 cm2⋅mL⋅min-1⋅g-1. This value was not statistically different from the Γi value of 
IL-10 capture in horse serum (4.12E-5 cm2⋅mL⋅min-1⋅g-1, p=0.577) and was not statistically 
different from capture in red blood cells resuspended in buffer (1.66E-5 cm2⋅mL⋅min-1⋅g-1, 
p=0.691). For IL-10 capture in red blood cells resuspended in plasma, the average Γ i value 
obtained over three trials was 2.48E-5 ± 5.7E-7 cm2⋅mL⋅min-1⋅g-1. This value was not statistically 
different from the Γi value of IL-10 capture in serum (4.12E-5 cm2⋅mL⋅min-1⋅g-1, p=0.456).  Total 
cytokine removal and overall trend of capture was exactly as seen in all previous IL-10 captures.  
These results indicate that there is no statistical difference in capture rates for IL-10 in buffer or 
any of the red blood cell suspensions. 
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Figure 46:  IL-10 capture in human plasma and red blood cells resuspended in human plasma 
 
In conclusion, capture of IL-6 in red blood cell suspensions of plasma prove that the presence of 
red blood cells was not significant and had no interaction with the beads or IL-6.   Capture of 
TNF and IL-10 in red blood cell suspensions of plasma were again as expected, proving that the 
presence of red blood cells was not significant and had no interaction with the TNF of IL-10.   
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5.4 CAPTURE OF CYTOKINES OF INTEREST HEALTHY HUMAN WHOLE 
BLOOD 
5.4.1 Capture of IL-6 in whole blood  
As a final set of experiments, we chose to spike IL-6 directly into 40% HCT healthy human 
whole blood and perform recirculation.  In this set of experiments, additional complexities 
inherent in whole blood suspensions such as the presence of white blood cells were hypothesized 
to possibly cause issues in capture rates. .  White blood cells make up approximately 1% of the 
total volume of whole blood in a healthy adult and consist of monocytes, neutrophils, basophils, 
and eosinophils.  These cells are crucial for the body’s immune response and many are 
responsible for the production of cytokines and chemokines involved in sepsis and septic shock.  
For example, activated monocytes produce IL-6 and activated macrophages produced IL-10 and 
TNF. 
For these capture experiments, shown in Figure 47, the average Γ i value obtained over 
three trials of IL-6 capture was 1.21E-5 ± 1.1E-6 cm2⋅mL⋅min-1⋅g-1. This value was statistically 
different from the Γ i value of previous IL-6 capture in red blood cells resuspended in plasma 
(3.80E-5 cm2⋅mL⋅min-1⋅g-1, p<0.001).  Total reduction of IL-6 spiked into whole blood was 
decreased more than 20% to only 70% removal compared to red blood cells resuspended in 
plasma with 93% total removal.   
These results suggest the presence of some underlying mechanism that results in 
modified capture rates.  We hypothesized that the reduction in capture of IL-6 was possibly due 
to one of two mechanisms: the production of cytokines by activated white blood cells present in 
the whole blood suspension or the adsorption of activated white blood cells and activated 
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platelets to the surface of the beads and subsequent production of cytokines.   The activation of 
white blood cells and platelets may be caused by the circuit and/or interaction with the beads.  
 
 
Figure 47:  IL-6 capture in whole human blood compared to capture of red blood cells 
resuspended in human plasma 
 
 
In order to test these hypotheses, two experiments were completed.  In the first, a sham 
experiment (circuit without a CAD) was completed to test whether whtie blood cells were 
prodcuing cytokines that would reduce overall capture rates.  The results of this experiment (not 
shown) indicate that cytokines are not being produced as concentration of IL-6 remained at or 
within 1% of the initial concentration.  The second experiment involved closing the loop to air 
and keeping it temperature controlled, as described in section 5.1.1, in order to reduce possible 
activation of white blood cells and platelets.  The results of this experiment are shown in Figure 
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48.  The Γ i value obtained over one trial was 1.55E-5 cm2⋅mL⋅min-1⋅g-1, an order or magnitude 
less than the Γi value for IL-6 capture in red blood cells resuspended in buffer.  Overall trend of 
capture was statistically the same to that of IL-6 spiked in whole blood.  These results show that 
closing the loop and keeping it temperature controlled have little effect on capture rates.  
However, results of SEM images from our colleagues in the Kellum Laboratory indicate that 
white blood cells are adsorbing onto the surface of the beads in significant numbers.  Figure 49 
shows the results of the SEM images, with the whole blood perfused beads showing significant 
platelet and leukocyte adsorption compared to the control with no blood flow.  The significant 
number of white blood cells adsorbed onto the surface of the beads also results in higher amounts 
of activation of the white blood cells as determined by flow cytometry analysis by our 
colleagues.  An increase in white blood cell activation due to the presence of the novel sorbet 
polymer could in turn produce significant amounts of cytokines, affecting capture rates seen in 
vitro.  Further investigation into this issue will be completed in the future.   
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Figure 48:  IL-6 capture in a modified experimental set up compared to capture in whole blood 
and capture in red blood cells resuspended in human plasma 
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Figure 49:  SEM images of the CytoSorb beads perfused with whole blood or no blood, as down 
by our colleagues in the Kellum Laboratory. A significant number of white blood cells are shown 
as adsorbed to the surface of the whole blood perfused bead. 
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5.4.2 Capture of TNF in whole blood  
As a final set of experiments, we chose to spike TNF directly into 40% HCT healthy human 
whole blood and perform recirculation.  For these capture experiments, shown in Figure 50, the 
average Γ i value obtained over three trials was 4.32E-6 ± 5.5E-7 cm2⋅mL⋅min-1⋅g-1. This value 
was not statistically different from the Γ i value of previous TNF capture in red blood cells 
resuspended in plasma (4.90E-6 cm2⋅mL⋅min-1⋅g-1, p=0.117).  Total reduction of TNF in red 
blood cells resuspended in plasma was decreased 10% to 46% removal compared to red blood 
cells resuspended in plasma with 56% total removal.  Unlike removal of IL-6, these results 
suggest that there is no effect of the presence of white blood cells on capture of TNF. 
 
 
Figure 50: TNF capture in whole human blood compared to capture of red blood cells 
resuspended in human plasma 
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5.4.3 Capture of IL-10 in whole blood  
For the final set of experiments in whole blood, shown in Figure 51, the average Γ i value 
obtained over three trials of IL-10 capture was 6.27E-6 ± 1.2E-6 cm2⋅mL⋅min-1⋅g-1. This value 
was statistically different from the Γ i value of previous IL-10 capture in red blood cells 
resuspended in plasma (2.48E-5 cm2⋅mL⋅min-1⋅g-1, p<0.01).  Total reduction of IL-10 spiked in 
whole blood was decreased nearly 20% to only 64% removal compared to red blood cells 
resuspended in buffer with 82% total removal.  Like IL-6 removal in whole blood, these results 
indicate an underlying mechanism responsible for the reduction in capture rates and could be 
attributed to the reduction in surface area due to significant white blood cell adsorption onto the 
bead surface. 
 
 
Figure 51: IL-10 capture in whole human blood compared to capture of red blood cells 
resuspended in human plasma 
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In conclusion, capture rates of IL-6 and IL-10 in whole blood were not as expected and had 
reduced removal, the mechanism behind which may include white blood cell adsorption to the 
bead and subsequent activation and production of white blood cells.  Additional experiments of 
capture of TNF in whole blood were as expected and had similar removal to those in plasma. All 
of the data from this chapter will be included in the systems model of sepsis being developed by 
our colleagues. 
 102 
6.0  SUMMARY AND CONCLUSIONS 
The goal of this thesis was to characterize and compare adsorption profiles of a novel sorbent 
polymer used for the treatment of sepsis using different devices, suspensions, and cytokines.  
The specific aims included characterizing adsorption profiles and model fits of the three main 
cytokines of interest in buffer and serum for our original baseline polymer; characterization and 
comparison of adsorption during a change in bead lots as well as expanding our knowledge of 
adsorption by investigating other cytokines of interest; characterization of a small diameter bead 
lot and the subsequent development of a newly engineered device for use with the smaller 
polymer; and finally the characterization of cytokine capture in whole blood and red blood cell 
suspensions. 
A mathematical model was previously developed in-house in order to guide development 
of the device and characteristics of the polymer used.  Our mathematical model was derived in 
order to quantify and compare removal of cytokines from suspensions using different bead sizes, 
flow rates, reservoir volumes, suspensions, etc. The analysis the following simple analytic 
expression for the removal rate of individual cytokines: 
 
    (8) 
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where Q is the volumetric flow rate, Vr is the suspension reservoir volume, mb is the mass of 
beads in the column, R is the radius of bead in the column, and ρ is the density of the polymer 
[44].  The unknown parameter Γi, which is specific to the cytokine i and the particular polymer, 
is defined as  
 
      (9) 
 
where Di is the effective diffusion coefficient of cytokine i in the beads, qimax is the maximum 
capacity of cytokine i per unit mass of bead, and Ki is the affinity constant from the Langmuir 
equilibrium adsorption isotherm [44]. 
Using this model, we discovered that the biocompatible baseline polymer was able to 
remove significant amounts of IL-6, TNF, IL-10, IL-1α, IL-1RA, HMG-B1, and IL-8 in both 
buffer and serum. A summary of the gamma values for our three main cytokines of interest for 
these experiments is shown below in Table 8.   
 
 
Table 8: Comparison of gamma (Γi) values for IL-6, TNF, and IL-10 in baseline polymer for 
buffer and serum 
 
 Buffer Serum 
IL-6 1.76E-4 5.08E-5 
TNF 4.30E-5 4.52E-6 
IL-10 1.86E-5 2.25E-5 
 
 
Further reduction of polymer diameter resulted in faster capture rates for several of the cytokines 
and the resulting development of the reCAD for use with small polymer was also significant, 
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providing a device with reduced shear for lower hemolysis. A summary of the gamma values for 
our three main cytokines of interest for these experiments is shown below in Table 9. 
 
Table 9: Gamma (Γi) values for IL-6, TNF, and IL-10 capture using small diameter polymer in 
the CAD and reCAD 
 
 Small bead 
CAD 
Small bead 
reCAD 
p value 
IL-6 2.60E-4 3.40E-6 =0.310 
TNF 4.77E-6 6.47E-6 =0.513 
IL-10 3.39E-5 1.38E-4 =0.369 
 
 
Finally, experimentation in red blood suspensions proved our hypothesis that the presence of red 
blood cells has no effect on capture; however, an underlying mechanism in capture of spiked 
whole blood results in a significant reduction of capture rates for both IL-6 and IL-10.  Our 
preliminary hypothesis is that white blood cells, which interact and adsorb to the surface of the 
polymer, may be producing certain cytokines, therefore changing the rate of capture for some of 
the cytokines of interest.  This mechanism will be investigated further in the future. A summary 
of the gamma values for our three main cytokines of interest for these experiments is shown 
below in Table 10. 
 
 
Table 10: Gamma (Γi) values for IL-6, TNF, and IL-10 capture in healthy human whole blood 
 
 IL-6 TNF IL-10 
Whole blood 1.21E-5  4.32E-6 6.27E-6 
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This characterization data is crucial not only for the validation and development of our own in-
house mathematical model that will be discussed later, but also for the development and 
calibration of a systems model of sepsis developed by our colleagues [43].  This systems model 
will ultimately stimulate the development and progression of sepsis in humans and the 
integration of a therapeutic CAD intervention protocol into the timecourse of sepsis to improve 
patient outcomes.  The work in this thesis provides a complete characterization of a novel 
sorbent polymer used for the treatment of sepsis.  With the data in this thesis, optimizations and 
developments to both the polymer and the device can be made, further advancing 
hemoadsorption technology. 
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APPENDIX A 
MATLAB® CODE FOR MATHEMATICAL MODEL 
A.1 ORIGINAL CODE 
A.1.1 CADs_ model_fitting.m 
% Script file to perform nonlinear regression and analysis for the cytokine 
% adsorbing device (CAD) model 
  
% cartridge and bead parameters 
global mb rho R Q Vr deltaV t_exp N  
mb=1.5; % mass of adsorbing beads in the CADS (g) 
rho=1.02; % density of adsorbing beads (g/ml) 
R=266.58; % radius of adsorbing beads (microns) 
R=R*10^-4; % work in cgs units 
  
% device operating parameters 
Q=0.8; % flowrate through device (ml/min) 
Vr=8; % initial reservoir volume (ml) 
deltaV=0.200; % sampling size that reduces the reservoir size at each time point 
warning off all 
  
% the experimental data below could also be inputed from a file 
  
% input time of sampling 
t_exp=[10^-4  
    15  
    30  
    60 
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    90 
    120 
    180 
    240];  
N=length(t_exp); 
tmax=t_exp(N)+t_exp(2); 
tspan=[t_exp(1) tmax]; 
  
% input experimentally measured cytokine values 
C_exp=[1 
0.49929865 
0.331467259 
0.151037565 
0.112290482 
0.08093236 
0.042398813 
0.026708655];  
  
% determine and evaluate initial guesses for best gamma and Ci 
gamma=1.e-7; % initial guess for the gamma value describing data set 
Ci=C_exp(1); % initial guess for the initial concentration value 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
  
  
% perform nonlinear regressions to estimate best gamma and Ci 
beta=[gamma Ci]; 
[betafit,resids,J]=nlinfit(t_exp,C_exp,'removal_predict',beta); 
confident = nlparci(betafit,resids,J);% 95% confidence intervals for each parameter 
gamma=betafit(1); 
Ci=betafit(2); 
  
% graphically evaluate best fit 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
figure 
plot(t_exp,C_exp,'o',t_out,C_out) 
axis([0 tmax 0 C_exp(1)]) 
xlabel('Circulation Time (mins)') 
ylabel('Cytokine Concentration') 
legend('Experimental', 'Model Prediction') 
%titletxt=sprintf(: Gamma_i = %.3e and C_i = %.2f',gamma,Ci); 
title('Best-fit predictions versus experimental data') 
labeltxt=sprintf('Gamma_i = %.3e \n C_i = %.2f',gamma,Ci); 
gtext(labeltxt); 
  
% output the final parameter values and confidence intervals 
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fprintf('Gamma_i = %.3e (w/ 95 percent CI from %.3e to 
%.3e)',gamma,confident(1,1),confident(1,2)) 
fprintf('\n\n C_i = %.2f (w/ 95 percent CI from %.2f to %.2f)',Ci,confident(2,1),confident(2,2)) 
fprintf('\n') 
A.1.2 Removal_predict.m 
function C_pred = removal_predict(beta,t); 
N=length(t); 
gamma=beta(1); 
Ci=beta(2); 
tspan=[0 t(N)]; 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
C_pred=interp1(t_out,C_out,t,'spline'); 
A.1.3 C_dot.m 
function y = C_dot(t,C,gamma); 
% function file for computing the time-derivative of cytokine concentartion 
% predicted by the model 
global mb rho R Q Vr deltaV t_exp N 
% adjust reservoir size for finite sampling size 
Vact=Vr; 
for n=1:N-2 
    if t>t_exp(n+1) Vact=Vact-deltaV; 
    end 
end 
y =-Q/Vact*(1-exp(-3/pi*mb/Q/R*sqrt(gamma/rho/t)))*C; 
A.2 MODIFIED CODE FOR SMALL BEAD CAPTURE 
A.2.1 reCADs_ model_fitting.m 
% script file to perform nonlinear regression and analysis for the cytokine 
% adsorbing device (CADS) model 
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% cartridge and bead parameters 
global mb rho R Q Vr deltaV t_exp N  
mb=1.5; 
rho=1.02;% mass of adsorbing beads in the CADS (g)rho=1.02; % density of adsorbing beads 
(g/ml) 
R=46.4; % radius of adsorbing beads (microns) 
R=R*10^-4; % work in cgs units 
% device operating parameters 
Q=0.8; % flowrate through device (ml/min) 
Vr=8; % initial reservoir volume (ml) 
deltaV=0.200; % sampling size that reduces the reservoir size at each time point 
warning off all 
  
% the experimental data below could also be inputted from a file 
% input time of sampling 
t_exp=[10^-4 
15 
30 
60 
90 
120 
180 
240];  
 
N=length(t_exp); 
tmax=t_exp(N)+t_exp(2); 
tspan=[t_exp(1) tmax]; 
 
% input experimentally measured cytokine values 
C_exp=[1 
0.392628866 
0.29151298 
0.174458939 
0.121045562 
0.114789769 
0.078233595 
0.078574256 
];  
  
% determine and evaluate initial guesses for best gamma and Ci 
gamma=1.0e-7; % initial guess for the gamma value describing data set 
Ci=C_exp(1); % initial guess for the initial concentration value 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
  
% perform nonlinear regressions to estimate best gamma and Ci 
beta=[gamma Ci]; 
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[betafit,resids,J]=nlinfit(t_exp,C_exp,'removal_predict',beta); 
confident = nlparci(betafit,resids,J);% 95% confidence intervals for each parameter 
gamma=betafit(1); 
Ci=betafit(2); 
  
%r squared value and if statement to run new code 
r2(1) = 1 - sum(resids.^2) / sum((C_exp - mean(C_exp)).^2); 
  
if r2(1)<0.9999 
     
% determine and evaluate initial guesses for best gamma and Ci 
gamma=1.0e-5; % initial guess for the gamma value describing data set 
Ci=C_exp(1); % initial guess for the initial concentration value 
Cinf=0.0001; % initial guess for C infinity 
[t_out,C_out]=ode45((@(t,C) C_smdot(t,C,gamma,Cinf)),tspan,Ci); 
  
% perform nonlinear regressions to estimate best gamma, Ci, Cinf 
beta=[gamma Ci Cinf]; 
[betafit,resids,J]=nlinfit(t_exp,C_exp,'sm_removal_predict',beta); 
confident = nlparci(betafit,resids,J);% 95% confidence intervals for each parameter 
gamma=betafit(1); 
Ci=betafit(2); 
Cinf=betafit(3); 
  
r2(2) = 1 - sum(resids.^2) / sum((C_exp - mean(C_exp)).^2); 
  
% graphically evaluate best fit 
[t_out,C_out]=ode45((@(t,C) C_smdot(t,C,gamma,Cinf)),tspan,Ci); 
figure 
plot(t_exp,C_exp,'o',t_out,C_out) 
axis([0 tmax 0 C_exp(1)]) 
xlabel('Circulation Time (mins)') 
ylabel('Cytokine Concentration') 
legend('Experimental', 'Model Prediction') 
%titletxt=sprintf(: Gamma_i = %.3e and C_i = %.2f',gamma,Ci); 
title('Best-fit predictions versus experimental data') 
labeltxt=sprintf('Gamma_i = %.3e \n C_i = %.2f \n C_i_n_f = %.3f',gamma,Ci,Cinf); 
gtext(labeltxt); 
  
% output the final parameter values and confidence intervals 
fprintf('Gamma_i = %.3e (w/ 95 percent CI from %.3e to 
%.3e)',gamma,confident(1,1),confident(1,2)) 
fprintf('\n\n C_i = %.2f (w/ 95 percent CI from %.2f to %.2f)',Ci,confident(2,1),confident(2,2)) 
fprintf('\n\n R squared = %.2f; %.2f',r2(1),r2(2)) 
fprintf('\n')  
  
 111 
else 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
figure 
plot(t_exp,C_exp,'o',t_out,C_out) 
axis([0 tmax 0 C_exp(1)]) 
xlabel('Circulation Time (mins)') 
ylabel('Cytokine Concentration') 
legend('Experimental', 'Model Prediction') 
%titletxt=sprintf(: Gamma_i = %.3e and C_i = %.2f',gamma,Ci); 
title('Best-fit predictions versus experimental data') 
labeltxt=sprintf('Gamma_i = %.3e \n C_i = %.2f',gamma,Ci); 
gtext(labeltxt); 
  
% output the final parameter values and confidence intervals 
fprintf('Gamma_i = %.3e (w/ 95 percent CI from %.3e to 
%.3e)',gamma,confident(1,1),confident(1,2)) 
fprintf('\n\n C_i = %.2f (w/ 95 percent CI from %.2f to %.2f)',Ci,confident(2,1),confident(2,2)) 
%fprintf('\n\n R squared = %.2f; %.2f',r2(1),r2(1)) 
fprintf('\n') 
end 
A.2.2 Removal_predict.m 
function C_pred = sm_removal_predict(beta,t); 
N=length(t); 
gamma=beta(1); 
Ci=beta(2); 
Cinf=beta(3); 
tspan=[0 t(N)]; 
[t_out,C_out]=ode45((@(t,C) C_smdot(t,C,gamma,Cinf)),tspan,Ci); 
C_pred=interp1(t_out,C_out,t,'spline'); 
A.2.3  C_smdot.m 
function y = C_smdot(t,C,gamma,Cinf) 
  
% function file for computing the time-derivative of cytokine concentartion 
% predicted by the model 
global mb rho R Q Vr deltaV t_exp N  
% adjust reservoir size for finite sampling size 
Vact=Vr; 
for n=1:N-2 
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    if t>t_exp(n+1) Vact=Vact-deltaV; 
    end 
end 
y =-Q/Vact*(1-exp(-3/sqrt(pi)*mb/Q/R*sqrt(gamma/rho/t)))*(C-Cinf); 
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